No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleonly females |
293145 |
2. Check conditionsNone |
293145 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
675 |
4. Check minimum number of eventsNone |
675 |
5. Include endpointsNone |
675 |
6. Filter based on genotype QC (FinnGen only) |
648 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF7
Similar endpoints
↥List of similar endpoints to
HSIL lesion of the vulva
based on the number of shared cases.
Similar with more cases:
- All dysplastic lesions of the vulva
- HSIL lesion of the cervix uteri, vagina or vulva
- All dysplastic lesions of the cervix uteri, vagina or vulva
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2936 | 2936 | - |
| Only index persons | 2789 | 2789 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | - |
| Only index persons | 0.10 | 0.10 | - |
| Median age at first event (years) | |||
| Whole population | - | 55.85 | - |
| Only index persons | - | 55.25 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 648 | 648 | - |
| Unadjusted period prevalence (%) | 0.23 | 0.23 | - |
| Median age at first event (years) | 57.25 | 57.25 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 675
- Matched controls
- 6750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N90.1
ICD-10 Finland
Moderate vulvar dysplasia
+∞
320.1
281
*
ULA02
NOMESCO Finland
Kolposcopy
48.7
307.7
545
535
LFB10
NOMESCO Finland
Excision of lesion of vulva or perineum
166.6
307.7
245
23
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
101.9
307.7
435
118
N90.2
ICD-10 Finland
Severe vulvar dysplasia, not elsewhere classified
+∞
307.7
394
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
13.3
265.1
407
693
LFB20
NOMESCO Finland
Destruction of lesion of vulva or perineum
116.6
242.6
124
13
LEB00
NOMESCO Finland
Biopsy of vagina
31.1
240.2
166
70
8077/2-C51.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of vulva, NOS
1495.5
226.6
208
*
N90.0
ICD-10 Finland
Mild vulvar dysplasia
106.4
178.1
92
10
D06BB10
ATC
imiquimod; topical
12.6
166.5
188
201
D07.1
ICD-10 Finland
Carcinoma in situ: Vulva
+∞
148.6
137
*
LFC00
NOMESCO Finland
Partial excision of vulva
587.8
147.5
141
*
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
9.0
140.2
211
324
A63.0
ICD-10 Finland
Anogenital (venereal) warts
14.0
132.3
132
115
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
6.9
119.5
246
521
L90.0
ICD-10 Finland
Lichen sclerosus et atrophicus
9.1
93.6
127
168
N76.6
ICD-10 Finland
Ulceration of vulva
23.9
88.8
65
30
LEB30
NOMESCO Finland
Destruction of lesion of vaginal mucosa
29.0
82.5
56
21
N89.1
ICD-10 Finland
Moderate vaginal dysplasia
50.4
80.7
47
10
R87.5
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal microbiological findings
12.5
69.3
71
63
LDA10
NOMESCO Finland
Curettage of cervix uteri
6.9
69.3
119
203
N87.0
ICD-10 Finland
Mild cervical dysplasia
9.4
68.3
87
105
D07AD01
ATC
clobetasol; topical
4.2
66.0
251
840
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
7.1
63.5
104
168
N89.0
ICD-10 Finland
Mild vaginal dysplasia
29.8
62.6
42
15
N90.8
ICD-10 Finland
Other specified noninflammatory disorders of vulva and perineum
14.2
57.7
54
41
N90.4
ICD-10 Finland
Leukoplakia of vulva
23.5
57.4
42
19
N90.9
ICD-10 Finland
Noninflammatory disorder of vulva and perineum, unspecified
22.3
56.3
42
20
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
3.4
52.8
391
1954
N87.1
ICD-10 Finland
Moderate cervical dysplasia
8.8
50.3
66
82
C51.01
ICD-10 Finland
Squamous cell carcinoma of the labium majus
467.1
44.8
44
*
8077/2-C52.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of vagina, NOS
234.9
43.4
44
*
D06BB04
ATC
podophyllotoxin; topical
5.7
43.2
87
171
N87.2
ICD-10 Finland
Severe cervical dysplasia, not elsewhere classified
7.8
41.7
60
83
C51.11
ICD-10 Finland
Squamous cell carcinoma of the labium minus
141.5
38.1
40
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.6
36.3
142
465
8071/2-C51.9
ICD-O-3
Differentiated intraepithelial neoplasia of vulva, NOS
+∞
35.7
34
*
8070/3-C51.9
ICD-O-3
Squamous cell carcinoma, NOS, of vulva, NOS
365.3
35.3
35
*
TLW99
NOMESCO Finland
Other minor surgical procedure in gynaecology
6.8
35.1
57
90
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
3.1
31.6
163
629
8077/2-C53.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of cervix uteri
8.1
28.3
39
51
N89.2
ICD-10 Finland
Severe vaginal dysplasia, not elsewhere classified
47.8
26.7
32
7
Y83.8
ICD-10 Finland
Other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
5.7
25.3
49
92
L04AA06
ATC
mycophenolic acid; systemic
8.1
23.6
32
41
J02AC01
ATC
fluconazole; systemic
2.3
23.1
409
2730
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
3.1
22.9
108
391
B01AB10
ATC
tinzaparin; parenteral
2.8
22.1
125
500
ZXC10
NOMESCO Finland
Use of laser
6.2
21.1
37
63
N90.3
ICD-10 Finland
Dysplasia of vulva, unspecified
113.6
20.7
22
*
G01AA10
ATC
clindamycin; vaginal
2.4
20.5
190
961
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
4.2
20.5
57
145
8070/2-C51.9
ICD-O-3
Squamous cell carcinoma in situ, NOS, of vulva, NOS
+∞
19.9
19
*
C51.81
ICD-10 Finland
Squamous cell carcinoma of the vulva
72.0
18.8
21
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.1
18.4
25
32
WX002
NOMESCO Finland
Sedation and analgesia
2.3
18.2
173
879
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
4.7
18.2
43
96
P01AB01
ATC
metronidazole; oral, rectal
2.0
18.2
367
2487
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
5.4
15.9
32
62
LDB20
NOMESCO Finland
Electrocoagulation or laser therapy of cervix uteri
7.4
15.8
23
32
LFD10
NOMESCO Finland
Vulvectomy and excision of regional lymph nodes
+∞
15.7
15
*
ZZR00
NOMESCO Finland
Flap of skin
5.8
15.2
28
50
L29.2
ICD-10 Finland
Pruritus vulvae
4.7
15.1
35
77
N94.1
ICD-10 Finland
Dyspareunia
7.0
14.9
23
34
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.0
14.9
23
34
WX320
NOMESCO Finland
Spinalanesthesy
2.0
14.8
211
1243
8070/3-C51.1
ICD-O-3
Squamous cell carcinoma, NOS, of labium minus
+∞
14.6
14
*
UKC02
NOMESCO Finland
Cystoscopy
2.5
14.6
97
417
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
14.1
171
948
G03CA03
ATC
estradiol; nasal, systemic, rectal, transdermal, vaginal
2.0
13.4
492
3903
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.6
13.1
81
336
E0000UV, ,
ATC
1.8
12.7
332
2353
2333B
ICD-9 Finland
Carcinoma in situ of breast and genito-urinary system, Other and unspecified female genital organs[CARCINOMA IN SITU VULVAE]
+∞
12.5
12
*
8077/2-C51.1
ICD-O-3
Squamous intraepithelial neoplasia, high grade of labium minus
+∞
12.5
12
*
8474
FHL
Coagulation, excision, or biopsy of local change (eg, condyloma, tumor) in operating room or anesthesia
20.5
12.5
18
9
WZC00
NOMESCO Finland
Treatment plan or consultation
1.8
12.3
286
1952
LCA06
NOMESCO Finland
Biopsy of endometrium
2.0
11.8
142
779
J01MA02
ATC
ciprofloxacin; systemic
1.8
11.8
270
1829
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
5.7
11.7
22
40
D07AC01
ATC
betamethasone; topical
1.8
11.6
274
1870
D07AB02
ATC
hydrocortisone butyrate; topical
1.8
11.5
240
1577
LFC96
NOMESCO Finland
Other partial excision of vulva or perineum
122.0
11.5
12
*
127
Kela drug reimbursment
Transplant complication
9.1
11.3
23
26
C51.9
ICD-10 Finland
Malignant neoplasm: Vulva, unspecified
35.7
11.3
14
*
PJD55
NOMESCO Finland
Block dissection of inguinal lymph nodes
35.7
11.3
14
*
LFE10
NOMESCO Finland
Plastic repair of vulva
17.4
11.2
17
10
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
11.2
331
2400
Z09.0
ICD-10 Finland
Follow-up examination after surgery for other conditions
2.3
11.0
89
417
WX408
NOMESCO Finland
General anesthesy, balanced
1.9
11.0
191
1185
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
10.9
101
500
X16
ICPC
Vulval symptom/complaint
4.4
10.9
27
63
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
4.8
10.8
24
51
A11CC03
ATC
alfacalcidol; systemic
4.8
10.8
24
51
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
1.9
10.6
174
1059
LC2AE
NOMESCO Finland
Ultrasound examination of uterus and parametria
2.1
10.5
116
616
8542/3-C51.9
ICD-O-3
Paget disease, extramammary of vulva, NOS
111.7
10.4
11
*
LFD00
NOMESCO Finland
Vulvectomy
111.7
10.4
11
*
WF002
NOMESCO Finland
Radical radiotherapy
3.6
10.3
34
98
TQW80
NOMESCO Finland
Local dermatologic skincare
4.4
10.1
25
58
B03XA02
ATC
darbepoetin alfa; parenteral
4.9
10.1
22
46
ZXC00
NOMESCO Finland
Use of diathermy
10.3
10.1
19
19
B01AB05
ATC
enoxaparin; parenteral
1.7
10.1
239
1619
TLC02
NOMESCO Finland
Simple extraction of IUD
2.9
10.0
49
180
L04AX01
ATC
azathioprine; systemic
3.2
9.8
38
122
J01EA01
ATC
trimethoprim; systemic
1.7
9.8
242
1656
R50.9
ICD-10 Finland
Fever, unspecified
2.0
9.7
110
588
R03AC02
ATC
salbutamol; inhalant
1.7
9.6
419
3325
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.7
9.5
53
208
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
101.4
9.4
10
*
PJ5AQ
NOMESCO Finland
Sentinell lymphnode SPECT with low dose CT
17.8
9.4
14
8
WX402
NOMESCO Finland
General anaesthesia
1.8
9.4
170
1061
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
2.5
9.3
59
247
R23.8
ICD-10 Finland
Other and unspecified skin changes
1.8
9.1
178
1134
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.9
9.1
20
42
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.1
9.1
92
471
N02AX02
ATC
tramadol; systemic, rectal
1.6
9.0
297
2179
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
2.3
9.0
74
349
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
8.9
283
2055
D05BB02
ATC
acitretin; oral
4.6
8.9
21
47
L57.0
ICD-10 Finland
Actinic keratosis
2.1
8.9
86
433
J01AA02
ATC
doxycycline; systemic
1.9
8.8
553
4786
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.7
8.7
204
1367
128
Kela drug reimbursment
Cancers of female genital organs
3.6
8.6
28
80
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
3.6
8.6
28
80
ZXE00
NOMESCO Finland
One hour or less
1.6
8.6
285
2088
LFW96
NOMESCO Finland
Other operation on vulva or perineum
27.9
8.5
11
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
1.8
8.5
164
1041
Z94.0
ICD-10 Finland
Kidney transplant status
9.6
8.3
16
17
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
14.7
8.2
13
9
A12AA04
ATC
calcium carbonate; oral
8.3
8.1
17
21
G01AF01
ATC
metronidazole; vaginal
1.9
8.0
106
598
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.5
7.9
19
43
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
7.9
7.9
17
22
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.0
7.9
97
533
C03CA01
ATC
furosemide; systemic
1.7
7.8
187
1254
A02BC02
ATC
pantoprazole; systemic
1.6
7.8
480
4042
R06.0
ICD-10 Finland
Dyspnoea
1.7
7.8
197
1340
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.0
7.8
90
484
X15
ICPC
Vaginal symptom/complaint other
2.6
7.7
46
187
Z01.4
ICD-10 Finland
Gynaecological examination (general)(routine)
1.7
7.7
181
1207
C51.00
ICD-10 Finland
Malignant tumor of the labium majus without histology
45.5
7.7
9
*
N76.3
ICD-10 Finland
Subacute and chronic vulvitis
4.4
7.7
19
44
E000001, ,
ATC
1.7
7.7
148
936
UJF32
NOMESCO Finland
Coloscopy
1.7
7.7
184
1235
LWA00
NOMESCO Finland
Repair of wound dehiscence in gynaecological surgery
18.6
7.6
11
6
J05AB01
ATC
aciclovir; systemic
1.7
7.6
184
1237
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
3.1
7.6
32
108
R2110
NOMESCO Finland
Giving the first information
2.2
7.6
63
298
J01FF01
ATC
clindamycin; systemic
1.7
7.5
189
1285
N02BE01
ATC
paracetamol; systemic, rectal
2.3
7.4
625
5715
L04AA01
ATC
[U] ciclosporin
6.1
7.4
19
32
Z3231
NOMESCO Finland
Registered nurse
1.7
7.4
188
1278
R87.7
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal histological findings
13.5
7.4
12
9
J01DB01
ATC
cefalexin; oral
1.8
7.4
570
5054
L43.8
ICD-10 Finland
Other lichen planus
3.7
7.4
23
64
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.1
7.4
74
378
LEB10
NOMESCO Finland
Excision of lesion of vagina
9.5
7.3
14
15
8077/2-C51.8
ICD-O-3
Squamous intraepithelial neoplasia, high grade of overlapping lesion of vulva
+∞
7.3
7
*
XX1AT
NOMESCO Finland
Other puncture with ultrasound guidance
5.9
7.3
19
33
JN3AD
NOMESCO Finland
Abdominal CT examination
1.9
7.2
93
518
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.6
7.2
291
2206
T89
ICPC
Diabetes insulin dependent
2.9
7.2
33
117
WZC30
NOMESCO Finland
Teaching
1.8
7.1
118
712
D28.0
ICD-10 Finland
Benign neoplasm: Vulva
8.0
7.1
15
19
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.8
7.1
108
636
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.7
7.1
38
147
G04BD12
ATC
mirabegron; oral
1.9
7.0
93
523
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
2.6
7.0
39
154
GD1AD
NOMESCO Finland
Thorax CT examination
2.4
7.0
46
197
M79.6
ICD-10 Finland
Pain in limb
1.5
6.9
338
2665
TQW40
NOMESCO Finland
Remowal of suture of skin
2.2
6.9
57
269
WX892
NOMESCO Finland
Monitored bed care
2.3
6.8
49
218
LFE96
NOMESCO Finland
Other repair of vulva or perineum
40.5
6.8
8
*
A63.8
ICD-10 Finland
Other specified predominantly sexually transmitted diseases
16.9
6.8
10
6
Z2221
NOMESCO Finland
Medical doctor
1.6
6.7
201
1418
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
22.8
6.7
9
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
1.8
6.7
104
616
SPAT1153
SPAT
Removal of sutures
1.6
6.6
213
1528
R42
ICD-10 Finland
Dizziness and giddiness
1.6
6.6
173
1181
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
3.3
6.6
24
74
0781C
ICD-9 Finland
Other diseases due to viruses and Chlamydiae, Viral warts[CONDYLOMA ACCUMINATUM]
10.2
6.6
12
12
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
1.9
6.5
92
528
Z01.2
ICD-10 Finland
Dental examination
1.5
6.5
333
2641
WX702
NOMESCO Finland
Supraglottic ventilation device
2.3
6.5
51
236
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
2.1
6.5
59
290
7020X
ICD-9 Finland
Other dermatoses, Actinic keratosis[DERMATOSES PRAECANCEROSAE ALIAE]
70.5
6.4
7
*
PJD45
NOMESCO Finland
Excision of inguinal lymph nodes
14.5
6.4
10
7
L04AD01
ATC
ciclosporin; systemic
4.1
6.4
17
42
ZXD10
NOMESCO Finland
Scheduled procedure
1.5
6.3
261
1974
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.4
6.3
44
193
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
1.9
6.2
87
498
ULC02
NOMESCO Finland
Hysteroscopy
2.1
6.2
55
268
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.3
6.1
44
196
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
2.8
6.1
29
105
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
8.7
6.1
12
14
137
Kela drug reimbursment
Uraemia requiring dialysis
10.1
6.0
11
11
ZXE10
NOMESCO Finland
More than one and less than three hours
1.5
6.0
248
1871
WF003
NOMESCO Finland
Adjuvant radiotherapy
2.8
6.0
29
106
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Kolposcopy
ULA02 [2001306679]
ULA02 [2001306679]
2.6e+00
3.8e+00
—
1.0e+50
4.5e+00
5.6e+00
4.8e+00
cases:19.35%
controls:1.74%
cases:22.62%
controls:0.66%
—
—
cases:33.18%
controls:0.00%
cases:6.12%
controls:0.07%
cases:52.86%
controls:0.42%
cases:64.04%
controls:1.50%
130
117
542
6598
152
44
520
6671
—
223
0
449
6715
41
5
629
6696
342
27
305
6434
349
82
196
5391
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
XLD00 [2001306651]
1.9e+00
2.8e+00
3.9e+00
1.0e+50
2.0e+00
4.3e+00
3.6e+00
cases:12.65%
controls:2.08%
cases:12.20%
controls:0.82%
cases:5.51%
controls:0.12%
cases:12.50%
controls:0.00%
cases:0.90%
controls:0.12%
cases:23.49%
controls:0.42%
cases:40.37%
controls:1.77%
85
140
587
6575
82
55
590
6660
37
8
635
6707
84
0
588
6715
6
8
664
6693
152
27
495
6434
220
97
325
5376
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
1.0e+00
2.5e+00
3.2e+00
—
3.4e+00
3.7e+00
2.7e+00
cases:45.24%
controls:22.90%
cases:55.36%
controls:9.22%
cases:27.38%
controls:1.58%
—
—
cases:33.13%
controls:1.70%
cases:79.13%
controls:8.70%
cases:81.10%
controls:22.80%
304
1538
368
5177
372
619
300
6096
184
106
488
6609
—
222
114
448
6587
512
562
135
5899
442
1248
103
4225
Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
49891-5 [3029511]
49891-5 [3029511]
1.6e+00
2.4e+00
2.9e+00
1.0e+50
2.5e+00
3.3e+00
2.4e+00
cases:4.91%
controls:1.06%
cases:4.32%
controls:0.40%
cases:1.64%
controls:0.09%
cases:4.17%
controls:0.00%
cases:0.90%
controls:0.07%
cases:9.89%
controls:0.39%
cases:12.29%
controls:1.22%
33
71
639
6644
29
27
643
6688
11
6
661
6709
28
0
644
6715
6
5
664
6696
64
25
583
6436
67
67
478
5406
Biopsy of vulva or perineum
LFB00 [2001306759]
LFB00 [2001306759]
3.8e+00
5.6e+00
1.0e+50
1.0e+50
—
1.0e+50
5.4e+00
cases:10.42%
controls:0.27%
cases:20.24%
controls:0.09%
cases:9.08%
controls:0.00%
cases:18.15%
controls:0.00%
—
—
cases:33.23%
controls:0.00%
cases:39.45%
controls:0.29%
70
18
602
6697
136
6
536
6709
61
0
611
6715
122
0
550
6715
—
215
0
432
6461
215
16
330
5457
Human papilloma virus identified in Specimen
11481-9 [3025130]
11481-9 [3025130]
2.6e+00
3.2e+00
—
1.0e+50
—
4.3e+00
3.7e+00
cases:4.91%
controls:0.39%
cases:6.55%
controls:0.28%
—
—
cases:4.76%
controls:0.00%
—
—
cases:14.06%
controls:0.22%
cases:19.27%
controls:0.58%
33
26
639
6689
44
19
628
6696
—
32
0
640
6715
—
91
14
556
6447
105
32
440
5441
clobetasol
D07AD01 [21602141]
D07AD01 [21602141]
1.5e+00
2.5e+00
3.3e+00
1.0e+50
2.4e+00
2.2e+00
1.8e+00
cases:11.61%
controls:2.92%
cases:13.84%
controls:1.27%
cases:3.57%
controls:0.13%
cases:0.74%
controls:0.00%
cases:2.24%
controls:0.21%
cases:8.35%
controls:0.96%
cases:18.17%
controls:3.47%
78
196
594
6519
93
85
579
6630
24
9
648
6706
5
0
667
6715
15
14
655
6687
54
62
593
6399
99
190
446
5283
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
R87.6 [45558487]
2.1e+00
3.0e+00
3.9e+00
1.0e+50
—
2.4e+00
2.2e+00
cases:10.86%
controls:1.47%
cases:11.90%
controls:0.69%
cases:4.17%
controls:0.09%
cases:3.13%
controls:0.00%
—
—
cases:4.17%
controls:0.40%
cases:10.64%
controls:1.32%
73
99
599
6616
80
46
592
6669
28
6
644
6709
21
0
651
6715
—
27
26
620
6435
58
72
487
5401
imiquimod
D06BB10 [21602092]
D06BB10 [21602092]
2.5e+00
3.6e+00
—
1.0e+50
—
4.5e+00
2.6e+00
cases:5.06%
controls:0.45%
cases:4.17%
controls:0.12%
—
—
cases:1.34%
controls:0.00%
—
—
cases:11.90%
controls:0.15%
cases:7.89%
controls:0.66%
34
30
638
6685
28
8
644
6707
—
9
0
663
6715
—
77
10
570
6451
43
36
502
5437
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
7.7e-01
1.8e+00
3.5e+00
1.0e+50
2.9e+00
2.5e+00
1.6e+00
cases:20.39%
controls:10.57%
cases:22.32%
controls:4.54%
cases:12.20%
controls:0.42%
cases:15.77%
controls:0.00%
cases:6.72%
controls:0.39%
cases:26.89%
controls:2.99%
cases:36.33%
controls:10.51%
137
710
535
6005
150
305
522
6410
82
28
590
6687
106
0
566
6715
45
26
625
6675
174
193
473
6268
198
575
347
4898
Anogenital (venereal) warts
A63.0 [45585929]
A63.0 [45585929]
2.0e+00
3.9e+00
—
1.0e+50
—
3.9e+00
3.3e+00
cases:3.27%
controls:0.48%
cases:5.65%
controls:0.12%
—
—
cases:3.72%
controls:0.00%
—
—
cases:4.95%
controls:0.11%
cases:8.62%
controls:0.35%
22
32
650
6683
38
8
634
6707
—
25
0
647
6715
—
32
7
615
6454
47
19
498
5454
Mild cervical dysplasia
N87.0 [45567868]
N87.0 [45567868]
2.9e+00
3.0e+00
—
1.0e+50
—
4.1e+00
2.9e+00
cases:3.57%
controls:0.21%
cases:2.68%
controls:0.13%
—
—
cases:3.72%
controls:0.00%
—
—
cases:5.10%
controls:0.09%
cases:5.87%
controls:0.35%
24
14
648
6701
18
9
654
6706
—
25
0
647
6715
—
33
6
614
6455
32
19
513
5454
Outpatient Visit
OP [9202]
OP [9202]
5.3e-01
1.1e+00
1.1e+00
5.7e+00
1.4e+00
1.7e+00
1.3e+00
cases:82.74%
controls:73.78%
cases:76.93%
controls:52.70%
cases:27.68%
controls:11.65%
cases:56.25%
controls:0.45%
cases:33.73%
controls:10.82%
cases:85.16%
controls:51.73%
cases:93.94%
controls:80.14%
556
4954
116
1761
517
3539
155
3176
186
782
486
5933
378
30
294
6685
226
725
444
5976
551
3342
96
3119
512
4386
33
1087
Severe cervical dysplasia, not elsewhere classified
N87.2 [45567869]
N87.2 [45567869]
2.2e+00
3.1e+00
—
1.0e+50
—
3.7e+00
3.0e+00
cases:2.08%
controls:0.24%
cases:2.68%
controls:0.12%
—
—
cases:2.38%
controls:0.00%
—
—
cases:4.17%
controls:0.11%
cases:5.69%
controls:0.29%
14
16
658
6699
18
8
654
6707
—
16
0
656
6715
—
27
7
620
6454
31
16
514
5457
Lichen sclerosus et atrophicus
L90.0 [45548221]
L90.0 [45548221]
2.4e+00
3.6e+00
—
1.0e+50
—
3.0e+00
3.0e+00
cases:6.10%
controls:0.57%
cases:9.38%
controls:0.28%
—
—
cases:4.91%
controls:0.00%
—
—
cases:6.80%
controls:0.37%
cases:11.56%
controls:0.64%
41
38
631
6677
63
19
609
6696
—
33
0
639
6715
—
44
24
603
6437
63
35
482
5438
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
18500-9 [3018006]
8.2e-01
2.0e+00
3.1e+00
1.0e+50
2.3e+00
1.9e+00
1.8e+00
cases:12.95%
controls:6.17%
cases:13.10%
controls:2.08%
cases:4.61%
controls:0.21%
cases:7.59%
controls:0.00%
cases:1.19%
controls:0.12%
cases:10.66%
controls:1.69%
cases:26.61%
controls:5.55%
87
414
585
6301
88
140
584
6575
31
14
641
6701
51
0
621
6715
8
8
662
6693
69
109
578
6352
145
304
400
5169
Biopsy of vaginal cervix
LDA20 [2001306656]
LDA20 [2001306656]
2.3e+00
2.9e+00
—
1.0e+50
—
3.7e+00
2.9e+00
cases:8.18%
controls:0.89%
cases:6.25%
controls:0.36%
—
—
cases:3.13%
controls:0.00%
—
—
cases:6.96%
controls:0.19%
cases:13.39%
controls:0.86%
55
60
617
6655
42
24
630
6691
—
21
0
651
6715
—
45
12
602
6449
73
47
472
5426
Moderate cervical dysplasia
N87.1 [45534145]
N87.1 [45534145]
2.1e+00
3.1e+00
—
1.0e+50
1.0e+50
3.3e+00
3.1e+00
cases:1.79%
controls:0.22%
cases:2.83%
controls:0.13%
—
—
cases:3.27%
controls:0.00%
cases:0.90%
controls:0.00%
cases:3.40%
controls:0.12%
cases:5.50%
controls:0.27%
12
15
660
6700
19
9
653
6706
—
22
0
650
6715
6
0
664
6701
22
8
625
6453
30
15
515
5458
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
LX1AE [2001306815]
8.8e-01
1.9e+00
2.2e+00
1.0e+50
2.6e+00
2.1e+00
1.4e+00
cases:4.91%
controls:2.10%
cases:5.21%
controls:0.85%
cases:1.04%
controls:0.12%
cases:4.32%
controls:0.00%
cases:1.64%
controls:0.12%
cases:6.03%
controls:0.74%
cases:8.81%
controls:2.34%
33
141
639
6574
35
57
637
6658
7
8
665
6707
29
0
643
6715
11
8
659
6693
39
48
608
6413
48
128
497
5345
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
1.0e+00
2.9e+00
—
1.0e+50
3.9e+00
2.0e+00
9.4e-01
cases:12.95%
controls:5.17%
cases:24.85%
controls:1.71%
—
—
cases:5.06%
controls:0.00%
cases:3.73%
controls:0.07%
cases:7.42%
controls:1.04%
cases:10.83%
controls:4.51%
87
347
585
6368
167
115
505
6600
—
34
0
638
6715
25
5
645
6696
48
67
599
6394
59
247
486
5226
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
1.4e+00
1.7e+00
2.2e+00
—
2.1e+00
1.7e+00
1.9e+00
cases:2.83%
controls:0.70%
cases:2.38%
controls:0.46%
cases:0.89%
controls:0.10%
—
—
cases:1.04%
controls:0.13%
cases:2.47%
controls:0.48%
cases:2.94%
controls:0.46%
19
47
653
6668
16
31
656
6684
6
7
666
6708
—
7
9
663
6692
16
31
631
6430
16
25
529
5448
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
LC2BE [2001306544]
7.9e-01
1.6e+00
2.5e+00
1.0e+50
2.0e+00
2.2e+00
1.6e+00
cases:13.10%
controls:6.40%
cases:10.27%
controls:2.23%
cases:3.57%
controls:0.31%
cases:8.18%
controls:0.00%
cases:1.64%
controls:0.22%
cases:13.14%
controls:1.72%
cases:22.94%
controls:5.83%
88
430
584
6285
69
150
603
6565
24
21
648
6694
55
0
617
6715
11
15
659
6686
85
111
562
6350
125
319
420
5154
Abnormal findings in specimens from female genital organs, abnormal microbiological findings
R87.5 [45563329]
R87.5 [45563329]
2.1e+00
2.4e+00
—
1.0e+50
—
3.3e+00
2.7e+00
cases:1.64%
controls:0.19%
cases:1.79%
controls:0.16%
—
—
cases:1.34%
controls:0.00%
—
—
cases:2.94%
controls:0.11%
cases:3.67%
controls:0.26%
11
13
661
6702
12
11
660
6704
—
9
0
663
6715
—
19
7
628
6454
20
14
525
5459
Curettage of cervix uteri
LDA10 [2001306655]
LDA10 [2001306655]
2.4e+00
2.6e+00
—
1.0e+50
—
2.9e+00
2.6e+00
cases:4.02%
controls:0.39%
cases:2.08%
controls:0.16%
—
—
cases:1.49%
controls:0.00%
—
—
cases:2.01%
controls:0.11%
cases:6.24%
controls:0.51%
27
26
645
6689
14
11
658
6704
—
10
0
662
6715
—
13
7
634
6454
34
28
511
5445
lidocaine; ointment
D04AB01 [21602020]
D04AB01 [21602020]
2.0e+00
2.6e+00
—
—
—
3.7e+00
2.1e+00
cases:3.13%
controls:0.45%
cases:2.08%
controls:0.16%
—
—
—
—
—
—
cases:4.33%
controls:0.11%
cases:4.77%
controls:0.58%
21
30
651
6685
14
11
658
6704
—
—
—
28
7
619
6454
26
32
519
5441
Therapeutic Radiology Physician
2085R0203X [38004006]
2085R0203X [38004006]
1.3e+00
2.0e+00
—
1.0e+50
—
3.7e+00
3.4e+00
cases:1.79%
controls:0.49%
cases:2.53%
controls:0.36%
—
—
cases:8.04%
controls:0.00%
—
—
cases:11.13%
controls:0.29%
cases:11.19%
controls:0.44%
12
33
660
6682
17
24
655
6691
—
54
0
618
6715
—
72
19
575
6442
61
24
484
5449
lidocaine
C05AD01 [21601618]
C05AD01 [21601618]
1.9e+00
2.6e+00
—
—
—
3.7e+00
2.1e+00
cases:2.98%
controls:0.45%
cases:2.08%
controls:0.16%
—
—
—
—
—
—
cases:4.33%
controls:0.11%
cases:4.77%
controls:0.58%
20
30
652
6685
14
11
658
6704
—
—
—
28
7
619
6454
26
32
519
5441
Systemic lupus erythematosus, unspecified
M32.9 [45553167]
M32.9 [45553167]
2.0e+00
2.6e+00
—
—
—
2.9e+00
2.3e+00
cases:1.49%
controls:0.21%
cases:1.19%
controls:0.09%
—
—
—
—
—
—
cases:1.39%
controls:0.08%
cases:1.47%
controls:0.15%
10
14
662
6701
8
6
664
6709
—
—
—
9
5
638
6456
8
8
537
5465
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
L04AA06 [21603896]
2.5e+00
2.5e+00
—
—
—
2.1e+00
2.3e+00
cases:2.38%
controls:0.19%
cases:1.64%
controls:0.13%
—
—
—
—
—
—
cases:1.39%
controls:0.17%
cases:2.20%
controls:0.22%
16
13
656
6702
11
9
661
6706
—
—
—
9
11
638
6450
12
12
533
5461
Nephrology
39 [38004479]
39 [38004479]
1.8e+00
1.8e+00
2.2e+00
—
1.4e+00
2.0e+00
1.4e+00
cases:3.57%
controls:0.60%
cases:2.98%
controls:0.51%
cases:1.49%
controls:0.16%
—
—
cases:0.75%
controls:0.18%
cases:3.09%
controls:0.45%
cases:3.30%
controls:0.86%
24
40
648
6675
20
34
652
6681
10
11
662
6704
—
5
12
665
6689
20
29
627
6432
18
47
527
5426
Conisation of cervix uteri using diathermy or laser
LDC03 [2001306664]
LDC03 [2001306664]
2.0e+00
2.4e+00
—
1.0e+50
—
2.3e+00
2.2e+00
cases:3.27%
controls:0.46%
cases:1.79%
controls:0.16%
—
—
cases:1.93%
controls:0.00%
—
—
cases:1.39%
controls:0.14%
cases:3.49%
controls:0.38%
22
31
650
6684
12
11
660
6704
—
13
0
659
6715
—
9
9
638
6452
19
21
526
5452
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
6.4e-01
1.3e+00
2.0e+00
—
1.7e+00
1.8e+00
1.4e+00
cases:8.18%
controls:4.48%
cases:4.02%
controls:1.15%
cases:1.34%
controls:0.18%
—
—
cases:1.49%
controls:0.28%
cases:5.87%
controls:0.98%
cases:8.81%
controls:2.36%
55
301
617
6414
27
77
645
6638
9
12
663
6703
—
10
19
660
6682
38
63
609
6398
48
129
497
5344
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
9.0e-01
1.5e+00
1.6e+00
—
2.5e+00
1.5e+00
8.7e-01
cases:19.64%
controls:9.04%
cases:11.16%
controls:2.81%
cases:1.49%
controls:0.31%
—
—
cases:2.54%
controls:0.21%
cases:10.97%
controls:2.71%
cases:16.70%
controls:7.75%
132
607
540
6108
75
189
597
6526
10
21
662
6694
—
17
14
653
6687
71
175
576
6286
91
424
454
5049
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
1.8e+00
8.0e-01
—
—
3.3e+00
2.5e+00
1.1e+00
cases:3.72%
controls:0.63%
cases:1.19%
controls:0.54%
—
—
—
—
cases:2.69%
controls:0.10%
cases:5.41%
controls:0.48%
cases:4.77%
controls:1.66%
25
42
647
6673
8
36
664
6679
—
—
18
7
652
6694
35
31
612
6430
26
91
519
5382
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
1.7e+00
2.2e+00
—
—
—
2.4e+00
2.1e+00
cases:1.93%
controls:0.34%
cases:1.49%
controls:0.16%
—
—
—
—
—
—
cases:1.39%
controls:0.12%
cases:1.65%
controls:0.20%
13
23
659
6692
10
11
662
6704
—
—
—
9
8
638
6453
9
11
536
5462
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
G03CA04 [21602518]
1.2e+00
1.7e+00
2.3e+00
—
—
1.7e+00
1.3e+00
cases:4.32%
controls:1.37%
cases:2.83%
controls:0.54%
cases:1.04%
controls:0.10%
—
—
—
—
cases:2.94%
controls:0.57%
cases:6.06%
controls:1.77%
29
92
643
6623
19
36
653
6679
7
7
665
6708
—
—
19
37
628
6424
33
97
512
5376
Biopsy of vagina
LEB00 [2001306684]
LEB00 [2001306684]
3.5e+00
—
1.0e+50
1.0e+50
—
—
4.5e+00
cases:5.80%
controls:0.19%
—
—
cases:1.79%
controls:0.00%
cases:2.38%
controls:0.00%
—
—
—
—
cases:11.19%
controls:0.15%
39
13
633
6702
—
12
0
660
6715
16
0
656
6715
—
—
61
8
484
5465
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
2.7e+00
—
—
—
—
2.6e+00
2.5e+00
cases:1.79%
controls:0.12%
—
—
—
—
—
—
—
—
cases:1.24%
controls:0.09%
cases:1.47%
controls:0.13%
12
8
660
6707
—
—
—
—
8
6
639
6455
8
7
537
5466
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
5.9e-02
4.9e-01
2.3e+00
—
3.2e+00
1.6e+00
6.4e-01
cases:11.16%
controls:10.59%
cases:6.85%
controls:4.29%
cases:4.61%
controls:0.46%
—
—
cases:7.01%
controls:0.31%
cases:15.15%
controls:3.51%
cases:20.37%
controls:11.88%
75
711
597
6004
46
288
626
6427
31
31
641
6684
—
47
21
623
6680
98
227
549
6234
111
650
434
4823
clindamycin; vaginal
G01AA10 [21602372]
G01AA10 [21602372]
1.1e+00
1.8e+00
—
—
2.5e+00
1.3e+00
9.8e-01
cases:8.93%
controls:3.26%
cases:5.80%
controls:0.98%
—
—
—
—
cases:0.90%
controls:0.07%
cases:3.25%
controls:0.93%
cases:7.52%
controls:2.96%
60
219
612
6496
39
66
633
6649
—
—
6
5
664
6696
21
60
626
6401
41
162
504
5311
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
7.8e-01
1.1e+00
1.7e+00
—
1.7e+00
1.3e+00
9.0e-01
cases:15.48%
controls:7.74%
cases:9.23%
controls:3.29%
cases:2.38%
controls:0.43%
—
—
cases:2.84%
controls:0.54%
cases:9.89%
controls:2.91%
cases:19.27%
controls:8.86%
104
520
568
6195
62
221
610
6494
16
29
656
6686
—
19
36
651
6665
64
188
583
6273
105
485
440
4988
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
8.8e-01
1.9e+00
—
1.0e+50
—
2.6e+00
2.0e+00
cases:4.17%
controls:1.77%
cases:5.80%
controls:0.89%
—
—
cases:2.83%
controls:0.00%
—
—
cases:5.41%
controls:0.42%
cases:8.26%
controls:1.24%
28
119
644
6596
39
60
633
6655
—
19
0
653
6715
—
35
27
612
6434
45
68
500
5405
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.2e-01
3.7e-01
1.2e+00
4.2e+00
1.0e+00
4.2e-01
1.2e-01
cases:51.49%
controls:48.52%
cases:55.21%
controls:46.00%
cases:35.57%
controls:14.27%
cases:28.13%
controls:0.58%
cases:31.19%
controls:13.83%
cases:57.03%
controls:46.60%
cases:63.85%
controls:61.12%
346
3258
326
3457
371
3089
301
3626
239
958
433
5757
189
39
483
6676
209
927
461
5774
369
3011
278
3450
348
3345
197
2128
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
5.3e-01
2.6e-01
1.6e+00
—
2.5e+00
1.3e+00
7.9e-01
cases:8.48%
controls:5.20%
cases:3.57%
controls:2.78%
cases:1.49%
controls:0.30%
—
—
cases:3.13%
controls:0.27%
cases:7.57%
controls:2.28%
cases:13.94%
controls:6.87%
57
349
615
6366
24
187
648
6528
10
20
662
6695
—
21
18
649
6683
49
147
598
6314
76
376
469
5097
Spinalanesthesia
WX320 [2001310799]
WX320 [2001310799]
3.6e-01
8.8e-01
—
1.0e+50
3.5e+00
2.0e+00
8.9e-01
cases:4.91%
controls:3.47%
cases:2.23%
controls:0.94%
—
—
cases:1.93%
controls:0.00%
cases:3.43%
controls:0.10%
cases:6.80%
controls:1.01%
cases:7.89%
controls:3.40%
33
233
639
6482
15
63
657
6652
—
13
0
659
6715
23
7
647
6694
44
65
603
6396
43
186
502
5287
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
6.6e-01
5.5e-01
—
1.0e+50
2.6e+00
1.9e+00
1.0e+00
cases:10.71%
controls:5.85%
cases:2.83%
controls:1.65%
—
—
cases:2.98%
controls:0.00%
cases:2.69%
controls:0.21%
cases:6.18%
controls:0.99%
cases:8.62%
controls:3.23%
72
393
600
6322
19
111
653
6604
—
20
0
652
6715
18
14
652
6687
40
64
607
6397
47
177
498
5296
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
7.8e-03
4.2e-01
2.2e+00
—
2.9e+00
1.1e+00
2.3e-01
cases:5.51%
controls:5.47%
cases:2.83%
controls:1.88%
cases:1.64%
controls:0.18%
—
—
cases:2.54%
controls:0.15%
cases:4.02%
controls:1.44%
cases:7.52%
controls:6.05%
37
367
635
6348
19
126
653
6589
11
12
661
6703
—
17
10
653
6691
26
93
621
6368
41
331
504
5142
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
6.7e-01
7.5e-01
—
1.0e+50
2.7e+00
1.7e+00
1.0e+00
cases:11.16%
controls:6.05%
cases:2.98%
controls:1.43%
—
—
cases:2.98%
controls:0.00%
cases:3.13%
controls:0.22%
cases:7.42%
controls:1.42%
cases:10.46%
controls:4.04%
75
406
597
6309
20
96
652
6619
—
20
0
652
6715
21
15
649
6686
48
92
599
6369
57
221
488
5252
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
4.9e-01
1.1e+00
—
—
2.4e+00
1.7e+00
7.1e-01
cases:3.72%
controls:2.32%
cases:2.53%
controls:0.83%
—
—
—
—
cases:1.34%
controls:0.12%
cases:4.48%
controls:0.82%
cases:5.87%
controls:2.98%
25
156
647
6559
17
56
655
6659
—
—
9
8
661
6693
29
53
618
6408
32
163
513
5310
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
5.7e-01
8.1e-01
1.4e+00
—
2.6e+00
1.4e+00
6.3e-01
cases:14.88%
controls:9.02%
cases:5.06%
controls:2.31%
cases:0.89%
controls:0.22%
—
—
cases:3.58%
controls:0.28%
cases:8.35%
controls:2.24%
cases:12.29%
controls:6.92%
100
606
572
6109
34
155
638
6560
6
15
666
6700
—
24
19
646
6682
54
145
593
6316
67
379
478
5094
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
2.1e-01
3.2e-01
8.3e-01
3.2e+00
1.0e+00
4.2e-01
1.5e-01
cases:42.71%
controls:37.69%
cases:31.25%
controls:24.81%
cases:9.67%
controls:4.45%
cases:2.98%
controls:0.12%
cases:11.19%
controls:4.33%
cases:33.38%
controls:24.75%
cases:48.81%
controls:45.06%
287
2531
385
4184
210
1666
462
5049
65
299
607
6416
20
8
652
6707
75
290
595
6411
216
1599
431
4862
266
2466
279
3007
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
T81.4 [45575538]
9.0e-01
1.2e+00
—
—
—
3.2e+00
1.6e+00
cases:2.68%
controls:1.10%
cases:1.34%
controls:0.42%
—
—
—
—
—
—
cases:5.72%
controls:0.25%
cases:4.40%
controls:0.88%
18
74
654
6641
9
28
663
6687
—
—
—
37
16
610
6445
24
48
521
5425
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
2.5e-01
2.0e-01
1.3e+00
1.0e+50
3.2e+00
1.6e+00
8.0e-01
cases:9.08%
controls:7.22%
cases:3.57%
controls:2.95%
cases:1.34%
controls:0.37%
cases:0.89%
controls:0.00%
cases:3.58%
controls:0.15%
cases:10.97%
controls:2.32%
cases:14.86%
controls:7.25%
61
485
611
6230
24
198
648
6517
9
25
663
6690
6
0
666
6715
24
10
646
6691
71
150
576
6311
81
397
464
5076
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
2.2e-01
3.4e-01
8.1e-01
2.8e+00
1.2e+00
5.2e-01
2.5e-01
cases:42.11%
controls:36.77%
cases:35.57%
controls:28.21%
cases:11.01%
controls:5.21%
cases:3.27%
controls:0.21%
cases:14.63%
controls:4.95%
cases:39.72%
controls:28.15%
cases:55.23%
controls:49.06%
283
2469
389
4246
239
1894
433
4821
74
350
598
6365
22
14
650
6701
98
332
572
6369
257
1819
390
4642
301
2685
244
2788
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
4.5e-01
5.7e-01
1.1e+00
—
2.0e+00
1.0e+00
5.4e-01
cases:40.03%
controls:29.89%
cases:15.77%
controls:9.55%
cases:2.83%
controls:0.97%
—
—
cases:6.57%
controls:0.97%
cases:21.17%
controls:8.79%
cases:38.53%
controls:26.84%
269
2007
403
4708
106
641
566
6074
19
65
653
6650
—
44
65
626
6636
137
568
510
5893
210
1469
335
4004
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
4.9e-01
9.2e-02
—
—
3.2e+00
1.8e+00
6.3e-01
cases:3.87%
controls:2.40%
cases:1.19%
controls:1.09%
—
—
—
—
cases:2.24%
controls:0.09%
cases:5.72%
controls:1.02%
cases:7.89%
controls:4.37%
26
161
646
6554
8
73
664
6642
—
—
15
6
655
6695
37
66
610
6395
43
239
502
5234
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
7.5e-01
1.4e+00
7.2e-01
1.6e+00
7.3e-01
1.3e+00
1.3e+00
cases:97.77%
controls:95.37%
cases:96.43%
controls:87.45%
cases:66.22%
controls:48.73%
cases:9.97%
controls:2.28%
cases:67.31%
controls:49.69%
cases:96.14%
controls:87.51%
cases:99.08%
controls:96.78%
657
6404
15
311
648
5872
24
843
445
3272
227
3443
67
153
605
6562
451
3330
219
3371
622
5654
25
807
540
5297
5
176
Outpatient Hospital
22 [8756]
22 [8756]
4.9e-01
7.8e-01
7.5e-01
—
2.1e+00
1.4e+00
8.5e-01
cases:33.78%
controls:23.75%
cases:13.24%
controls:6.52%
cases:1.93%
controls:0.92%
—
—
cases:6.57%
controls:0.88%
cases:18.70%
controls:5.20%
cases:30.46%
controls:15.71%
227
1595
445
5120
89
438
583
6277
13
62
659
6653
—
44
59
626
6642
121
336
526
6125
166
860
379
4613
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
2.3e-01
3.5e-01
8.0e-01
2.8e+00
1.2e+00
5.1e-01
2.4e-01
cases:42.71%
controls:37.14%
cases:36.01%
controls:28.46%
cases:11.16%
controls:5.33%
cases:3.27%
controls:0.21%
cases:14.93%
controls:5.13%
cases:39.88%
controls:28.49%
cases:55.41%
controls:49.35%
287
2494
385
4221
242
1911
430
4804
75
358
597
6357
22
14
650
6701
100
344
570
6357
258
1841
389
4620
302
2701
243
2772
Emergency Room Visit
ER [9203]
ER [9203]
4.2e-01
7.3e-01
1.1e+00
—
1.7e+00
8.9e-01
7.8e-01
cases:41.37%
controls:31.60%
cases:19.64%
controls:10.51%
cases:4.02%
controls:1.40%
—
—
cases:4.93%
controls:0.98%
cases:21.17%
controls:9.97%
cases:44.40%
controls:26.82%
278
2122
394
4593
132
706
540
6009
27
94
645
6621
—
33
66
637
6635
137
644
510
5817
242
1468
303
4005
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
G03CA03 [21602517]
5.0e-01
7.0e-01
4.9e-01
2.3e+00
5.4e-01
6.7e-01
7.7e-01
cases:38.69%
controls:27.77%
cases:33.63%
controls:20.10%
cases:8.04%
controls:5.08%
cases:1.49%
controls:0.15%
cases:8.51%
controls:5.13%
cases:33.08%
controls:20.17%
cases:47.52%
controls:29.49%
260
1865
412
4850
226
1350
446
5365
54
341
618
6374
10
10
662
6705
57
344
613
6357
214
1303
433
5158
259
1614
286
3859
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
2.1e-01
3.9e-01
5.7e-01
2.5e+00
9.8e-01
6.0e-01
3.3e-01
cases:38.84%
controls:33.91%
cases:30.06%
controls:22.50%
cases:7.29%
controls:4.26%
cases:1.79%
controls:0.15%
cases:9.40%
controls:3.76%
cases:34.47%
controls:22.32%
cases:51.19%
controls:43.03%
261
2277
411
4438
202
1511
470
5204
49
286
623
6429
12
10
660
6705
63
252
607
6449
223
1442
424
5019
279
2355
266
3118
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
6.4e-01
-2.8e-01
—
1.0e+50
2.3e+00
1.4e+00
1.0e+00
cases:10.42%
controls:5.76%
cases:1.04%
controls:1.37%
—
—
cases:1.49%
controls:0.00%
cases:1.34%
controls:0.13%
cases:3.55%
controls:0.93%
cases:7.89%
controls:3.01%
70
387
602
6328
7
92
665
6623
—
10
0
662
6715
9
9
661
6692
23
60
624
6401
43
165
502
5308
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
LC2AE [2001306543]
5.2e-01
1.7e+00
—
1.0e+50
—
2.1e+00
1.6e+00
cases:2.08%
controls:1.25%
cases:2.08%
controls:0.40%
—
—
cases:0.89%
controls:0.00%
—
—
cases:2.63%
controls:0.34%
cases:4.95%
controls:1.06%
14
84
658
6631
14
27
658
6688
—
6
0
666
6715
—
17
22
630
6439
27
58
518
5415
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
4.3e-01
6.1e-01
1.5e+00
—
1.5e+00
8.5e-01
3.9e-01
cases:18.90%
controls:13.18%
cases:10.71%
controls:6.14%
cases:3.72%
controls:0.85%
—
—
cases:3.43%
controls:0.78%
cases:13.60%
controls:6.33%
cases:25.32%
controls:18.62%
127
885
545
5830
72
412
600
6303
25
57
647
6658
—
23
52
647
6649
88
409
559
6052
138
1019
407
4454
tacrolimus; oral, parenteral
L04AD02 [21603925]
L04AD02 [21603925]
—
—
—
—
—
2.8e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:1.24%
controls:0.08%
cases:1.10%
controls:0.09%
—
—
—
—
—
8
5
639
6456
6
5
539
5468
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.9e-01
3.3e-01
7.2e-01
2.6e+00
1.1e+00
4.9e-01
1.7e-01
cases:44.94%
controls:40.27%
cases:40.63%
controls:33.00%
cases:12.80%
controls:6.64%
cases:3.42%
controls:0.25%
cases:16.57%
controls:6.28%
cases:44.67%
controls:32.98%
cases:57.06%
controls:52.95%
302
2704
370
4011
273
2216
399
4499
86
446
586
6269
23
17
649
6698
111
421
559
6280
289
2131
358
4330
311
2898
234
2575
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
5.6e-01
4.8e-01
1.1e+00
—
1.9e+00
7.7e-01
4.0e-01
cases:16.22%
controls:9.93%
cases:9.08%
controls:5.81%
cases:2.68%
controls:0.91%
—
—
cases:5.52%
controls:0.84%
cases:10.97%
controls:5.40%
cases:19.63%
controls:14.01%
109
667
563
6048
61
390
611
6325
18
61
654
6654
—
37
56
633
6645
71
349
576
6112
107
767
438
4706
podophyllotoxin
D06BB04 [21602086]
D06BB04 [21602086]
2.1e+00
3.2e+00
—
—
—
—
—
cases:3.72%
controls:0.48%
cases:2.38%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
25
32
647
6683
16
7
656
6708
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.3e-01
3.3e-01
7.2e-01
2.5e+00
1.2e+00
4.9e-01
3.0e-01
cases:33.48%
controls:28.52%
cases:29.76%
controls:23.37%
cases:8.93%
controls:4.54%
cases:2.38%
controls:0.21%
cases:13.43%
controls:4.48%
cases:33.69%
controls:23.76%
cases:48.44%
controls:41.15%
225
1915
447
4800
200
1569
472
5146
60
305
612
6410
16
14
656
6701
90
300
580
6401
218
1535
429
4926
264
2252
281
3221
Other specified noninflammatory disorders of vulva and perineum
N90.8 [45582428]
N90.8 [45582428]
2.5e+00
1.0e+50
1.0e+50
—
—
—
2.7e+00
cases:1.04%
controls:0.09%
cases:2.53%
controls:0.00%
cases:2.38%
controls:0.00%
—
—
—
—
—
—
cases:1.65%
controls:0.11%
7
6
665
6709
17
0
655
6715
16
0
656
6715
—
—
—
9
6
536
5467
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83.9 [45547252]
Y83.9 [45547252]
9.7e-01
—
—
—
—
3.0e+00
2.2e+00
cases:0.74%
controls:0.28%
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.11%
cases:2.20%
controls:0.26%
5
19
667
6696
—
—
—
—
14
7
633
6454
12
14
533
5459
Inpatient Visit
IP [9201]
IP [9201]
3.6e-01
7.6e-02
—
1.0e+50
3.2e+00
1.4e+00
5.3e-01
cases:9.08%
controls:6.54%
cases:3.13%
controls:2.90%
—
—
cases:1.64%
controls:0.00%
cases:5.07%
controls:0.22%
cases:9.58%
controls:2.62%
cases:15.05%
controls:9.41%
61
439
611
6276
21
195
651
6520
—
11
0
661
6715
34
15
636
6686
62
169
585
6292
82
515
463
4958
Other gynecological ultrasound examination
LX1XE [2001306816]
LX1XE [2001306816]
8.0e-01
1.9e+00
—
—
—
2.5e+00
2.6e+00
cases:0.89%
controls:0.40%
cases:0.89%
controls:0.13%
—
—
—
—
—
—
cases:1.08%
controls:0.09%
cases:4.04%
controls:0.31%
6
27
666
6688
6
9
666
6706
—
—
—
7
6
640
6455
22
17
523
5456
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
5.3e-01
1.1e+00
1.1e+00
—
1.8e+00
1.6e+00
6.6e-01
cases:5.80%
controls:3.51%
cases:3.87%
controls:1.36%
cases:0.74%
controls:0.24%
—
—
cases:1.04%
controls:0.18%
cases:4.33%
controls:0.94%
cases:7.34%
controls:3.95%
39
236
633
6479
26
91
646
6624
5
16
667
6699
—
7
12
663
6689
28
61
619
6400
40
216
505
5257
Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection
69002-4 [40771527]
69002-4 [40771527]
1.9e+00
3.1e+00
—
1.0e+50
—
—
—
cases:1.19%
controls:0.18%
cases:1.64%
controls:0.07%
—
—
cases:1.93%
controls:0.00%
—
—
—
—
—
—
8
12
664
6703
11
5
661
6710
—
13
0
659
6715
—
—
—
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.2e+00
1.4e+00
1.8e+00
—
—
1.5e+00
8.9e-01
cases:6.25%
controls:2.04%
cases:2.53%
controls:0.63%
cases:0.89%
controls:0.15%
—
—
—
—
cases:2.94%
controls:0.65%
cases:3.67%
controls:1.53%
42
137
630
6578
17
42
655
6673
6
10
666
6705
—
—
19
42
628
6419
20
84
525
5389
Tacrolimus [Mass/volume] in Blood
11253-2 [3026250]
11253-2 [3026250]
—
—
—
—
—
2.5e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.93%
controls:0.08%
cases:1.10%
controls:0.09%
—
—
—
—
—
6
5
641
6456
6
5
539
5468
Surface analgesia on skin or mucosa
WX105 [2001310765]
WX105 [2001310765]
8.4e-01
1.1e+00
—
1.0e+50
—
2.3e+00
1.7e+00
cases:3.42%
controls:1.50%
cases:1.19%
controls:0.39%
—
—
cases:0.74%
controls:0.00%
—
—
cases:3.55%
controls:0.36%
cases:6.79%
controls:1.33%
23
101
649
6614
8
26
664
6689
—
5
0
667
6715
—
23
23
624
6438
37
73
508
5400
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
5.5e-01
6.5e-01
-1.0e+50
—
2.3e+00
1.8e+00
7.7e-01
cases:5.36%
controls:3.16%
cases:1.64%
controls:0.86%
cases:0.00%
controls:0.10%
—
—
cases:1.19%
controls:0.12%
cases:4.64%
controls:0.82%
cases:6.42%
controls:3.07%
36
212
636
6503
11
58
661
6657
0
7
672
6708
—
8
8
662
6693
30
53
617
6408
35
168
510
5305
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
2.0e-01
2.3e-01
6.7e-01
2.7e+00
1.1e+00
3.7e-01
2.2e-01
cases:32.74%
controls:28.47%
cases:27.83%
controls:23.51%
cases:9.38%
controls:5.00%
cases:2.83%
controls:0.19%
cases:12.69%
controls:4.73%
cases:30.91%
controls:23.56%
cases:43.67%
controls:38.42%
220
1912
452
4803
187
1579
485
5136
63
336
609
6379
19
13
653
6702
85
317
585
6384
200
1522
447
4939
238
2103
307
3370
darbepoetin alfa; parenteral
B03XA02 [21601134]
B03XA02 [21601134]
2.5e+00
2.3e+00
—
—
—
1.8e+00
1.5e+00
cases:1.04%
controls:0.09%
cases:1.04%
controls:0.10%
—
—
—
—
—
—
cases:0.93%
controls:0.15%
cases:1.28%
controls:0.29%
7
6
665
6709
7
7
665
6708
—
—
—
6
10
641
6451
7
16
538
5457
Use of laser
ZXC10 [2001311360]
ZXC10 [2001311360]
2.4e+00
—
—
—
—
—
2.3e+00
cases:1.19%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.11%
8
7
664
6708
—
—
—
—
—
6
6
539
5467
Dyspareunia
N94.1 [45534149]
N94.1 [45534149]
1.7e+00
2.7e+00
—
—
—
—
2.0e+00
cases:0.89%
controls:0.16%
cases:1.34%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.15%
6
11
666
6704
9
6
663
6709
—
—
—
—
6
8
539
5465
Vulval symptom/complaint
X16 [2002001301]
X16 [2002001301]
—
2.6e+00
—
—
—
—
2.1e+00
—
—
cases:1.19%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.16%
—
8
6
664
6709
—
—
—
—
7
9
538
5464
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
1.8e-01
2.6e-01
6.8e-01
2.5e+00
1.0e+00
4.0e-01
1.4e-01
cases:48.36%
controls:43.95%
cases:43.45%
controls:37.29%
cases:14.73%
controls:8.06%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.49%
cases:47.45%
controls:37.81%
cases:60.00%
controls:56.71%
325
2951
347
3764
292
2504
380
4211
99
541
573
6174
24
20
648
6695
125
502
545
6199
307
2443
340
4018
327
3104
218
2369
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
1.8e-01
2.6e-01
6.8e-01
2.5e+00
1.0e+00
4.0e-01
1.3e-01
cases:48.36%
controls:44.01%
cases:43.45%
controls:37.30%
cases:14.73%
controls:8.06%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.49%
cases:47.45%
controls:37.81%
cases:60.00%
controls:56.73%
325
2955
347
3760
292
2505
380
4210
99
541
573
6174
24
20
648
6695
125
502
545
6199
307
2443
340
4018
327
3105
218
2368
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
1.8e-01
2.6e-01
6.7e-01
2.5e+00
1.0e+00
3.9e-01
1.3e-01
cases:48.36%
controls:44.01%
cases:43.45%
controls:37.32%
cases:14.73%
controls:8.09%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.51%
cases:47.45%
controls:37.83%
cases:60.00%
controls:56.75%
325
2955
347
3760
292
2506
380
4209
99
543
573
6172
24
20
648
6695
125
503
545
6198
307
2444
340
4017
327
3106
218
2367
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
1.8e-01
2.6e-01
6.7e-01
2.5e+00
1.0e+00
4.0e-01
1.3e-01
cases:48.36%
controls:43.98%
cases:43.60%
controls:37.38%
cases:14.73%
controls:8.12%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.52%
cases:47.60%
controls:37.86%
cases:60.00%
controls:56.79%
325
2953
347
3762
293
2510
379
4205
99
545
573
6170
24
20
648
6695
125
504
545
6197
308
2446
339
4015
327
3108
218
2365
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
1.8e-01
2.5e-01
6.7e-01
2.5e+00
1.0e+00
4.0e-01
1.3e-01
cases:48.36%
controls:44.01%
cases:43.45%
controls:37.35%
cases:14.73%
controls:8.10%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.52%
cases:47.45%
controls:37.81%
cases:60.00%
controls:56.77%
325
2955
347
3760
292
2508
380
4207
99
544
573
6171
24
20
648
6695
125
504
545
6197
307
2443
340
4018
327
3107
218
2366
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
1.7e-01
2.7e-01
6.7e-01
2.5e+00
1.0e+00
4.0e-01
1.3e-01
cases:48.36%
controls:44.10%
cases:43.75%
controls:37.36%
cases:14.73%
controls:8.10%
cases:3.57%
controls:0.30%
cases:18.66%
controls:7.52%
cases:47.45%
controls:37.81%
cases:60.00%
controls:56.82%
325
2961
347
3754
294
2509
378
4206
99
544
573
6171
24
20
648
6695
125
504
545
6197
307
2443
340
4018
327
3110
218
2363
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
1.7e-01
2.5e-01
6.8e-01
2.5e+00
1.0e+00
4.0e-01
1.4e-01
cases:48.21%
controls:43.90%
cases:43.30%
controls:37.24%
cases:14.73%
controls:8.07%
cases:3.57%
controls:0.30%
cases:18.51%
controls:7.51%
cases:47.45%
controls:37.73%
cases:60.00%
controls:56.66%
324
2948
348
3767
291
2501
381
4214
99
542
573
6173
24
20
648
6695
124
503
546
6198
307
2438
340
4023
327
3101
218
2372
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
1.1e-01
1.7e-01
5.7e-01
3.5e+00
5.5e-01
1.8e-01
7.6e-02
cases:69.20%
controls:66.87%
cases:64.88%
controls:60.89%
cases:38.84%
controls:26.36%
cases:35.71%
controls:1.67%
cases:38.21%
controls:26.23%
cases:66.46%
controls:62.37%
cases:75.78%
controls:74.37%
465
4490
207
2225
436
4089
236
2626
261
1770
411
4945
240
112
432
6603
256
1758
414
4943
430
4030
217
2431
413
4070
132
1403
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
3.2e-01
2.5e-01
1.6e+00
—
1.5e+00
7.2e-01
4.2e-01
cases:25.74%
controls:20.15%
cases:12.50%
controls:9.99%
cases:5.51%
controls:1.15%
—
—
cases:4.93%
controls:1.13%
cases:17.62%
controls:9.43%
cases:33.03%
controls:24.48%
173
1353
499
5362
84
671
588
6044
37
77
635
6638
—
33
76
637
6625
114
609
533
5852
180
1340
365
4133
Other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83.8 [45585761]
Y83.8 [45585761]
—
-1.0e+50
—
—
—
2.8e+00
1.7e+00
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:2.32%
controls:0.14%
cases:1.83%
controls:0.33%
—
0
9
672
6706
—
—
—
15
9
632
6452
10
18
535
5455
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
5.7e-01
2.2e-01
—
1.0e+50
1.9e+00
1.5e+00
5.8e-01
cases:9.82%
controls:5.81%
cases:2.68%
controls:2.16%
—
—
cases:1.49%
controls:0.00%
cases:1.64%
controls:0.24%
cases:7.26%
controls:1.78%
cases:11.01%
controls:6.47%
66
390
606
6325
18
145
654
6570
—
10
0
662
6715
11
16
659
6685
47
115
600
6346
60
354
485
5119
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
6.2e-01
6.9e-01
—
—
2.2e+00
1.6e+00
7.3e-01
cases:5.21%
controls:2.87%
cases:1.93%
controls:0.98%
—
—
—
—
cases:1.19%
controls:0.13%
cases:4.33%
controls:0.90%
cases:6.42%
controls:3.22%
35
193
637
6522
13
66
659
6649
—
—
8
9
662
6692
28
58
619
6403
35
176
510
5297
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
1.3e+00
1.1e+00
—
—
—
1.1e+00
1.1e+00
cases:3.72%
controls:1.09%
cases:2.08%
controls:0.73%
—
—
—
—
—
—
cases:2.01%
controls:0.67%
cases:4.40%
controls:1.55%
25
73
647
6642
14
49
658
6666
—
—
—
13
43
634
6418
24
85
521
5388
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
9.6e-01
1.8e+00
—
—
—
1.3e+00
1.6e+00
cases:2.53%
controls:0.98%
cases:1.79%
controls:0.31%
—
—
—
—
—
—
cases:0.93%
controls:0.25%
cases:3.85%
controls:0.82%
17
66
655
6649
12
21
660
6694
—
—
—
6
16
641
6445
21
45
524
5428
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
4.3e-01
5.7e-01
1.0e+00
—
1.5e+00
7.4e-01
3.3e-01
cases:17.11%
controls:11.85%
cases:11.31%
controls:6.72%
cases:2.38%
controls:0.86%
—
—
cases:3.13%
controls:0.72%
cases:14.37%
controls:7.44%
cases:26.06%
controls:20.14%
115
796
557
5919
76
451
596
6264
16
58
656
6657
—
21
48
649
6653
93
481
554
5980
142
1102
403
4371
Inpatient Hospital
21 [8717]
21 [8717]
3.9e-01
6.1e-01
5.5e-01
—
1.6e+00
1.0e+00
5.9e-01
cases:39.58%
controls:30.74%
cases:15.77%
controls:9.20%
cases:2.23%
controls:1.30%
—
—
cases:6.27%
controls:1.30%
cases:20.09%
controls:8.11%
cases:33.21%
controls:21.63%
266
2064
406
4651
106
618
566
6097
15
87
657
6628
—
42
87
628
6614
130
524
517
5937
181
1184
364
4289
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
6.2e-01
6.3e-01
2.4e+00
—
—
1.8e+00
4.6e-01
cases:3.42%
controls:1.88%
cases:1.34%
controls:0.71%
cases:1.34%
controls:0.12%
—
—
—
—
cases:4.02%
controls:0.67%
cases:3.30%
controls:2.12%
23
126
649
6589
9
48
663
6667
9
8
663
6707
—
—
26
43
621
6418
18
116
527
5357
Giving the first information
R2110 [2001310194]
R2110 [2001310194]
—
2.4e+00
—
1.0e+50
—
1.4e+00
1.8e+00
—
—
cases:1.19%
controls:0.10%
—
—
cases:0.89%
controls:0.00%
—
—
cases:0.77%
controls:0.19%
cases:2.94%
controls:0.51%
—
8
7
664
6708
—
6
0
666
6715
—
5
12
642
6449
16
28
529
5445
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
3.2e-01
4.0e-01
2.5e-01
2.4e+00
5.0e-01
6.3e-01
4.1e-01
cases:28.13%
controls:22.11%
cases:19.64%
controls:14.07%
cases:3.13%
controls:2.46%
cases:1.19%
controls:0.10%
cases:3.58%
controls:2.21%
cases:21.79%
controls:12.89%
cases:38.35%
controls:29.12%
189
1485
483
5230
132
945
540
5770
21
165
651
6550
8
7
664
6708
24
148
646
6553
141
833
506
5628
209
1594
336
3879
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
Z09.0 [45576131]
5.3e-01
1.5e+00
—
—
—
2.5e+00
1.7e+00
cases:1.49%
controls:0.88%
cases:0.89%
controls:0.19%
—
—
—
—
—
—
cases:2.01%
controls:0.17%
cases:2.94%
controls:0.57%
10
59
662
6656
6
13
666
6702
—
—
—
13
11
634
6450
16
31
529
5442
Multidisciplinary treatment meeting
WZC20 [2001310890]
WZC20 [2001310890]
1.5e+00
9.7e-01
—
—
—
2.6e+00
9.0e-01
cases:1.79%
controls:0.40%
cases:0.74%
controls:0.28%
—
—
—
—
—
—
cases:2.47%
controls:0.19%
cases:1.47%
controls:0.60%
12
27
660
6688
5
19
667
6696
—
—
—
16
12
631
6449
8
33
537
5440
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
4.2e-01
3.9e-01
—
—
2.0e+00
1.2e+00
7.8e-01
cases:8.18%
controls:5.52%
cases:2.98%
controls:2.04%
—
—
—
—
cases:2.24%
controls:0.30%
cases:5.10%
controls:1.52%
cases:10.28%
controls:4.97%
55
371
617
6344
20
137
652
6578
—
—
15
20
655
6681
33
98
614
6363
56
272
489
5201
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
2.4e-01
5.4e-01
1.5e+00
—
2.2e+00
5.7e-01
4.6e-01
cases:6.85%
controls:5.48%
cases:4.61%
controls:2.74%
cases:1.64%
controls:0.39%
—
—
cases:2.39%
controls:0.28%
cases:4.64%
controls:2.68%
cases:13.58%
controls:9.06%
46
368
626
6347
31
184
641
6531
11
26
661
6689
—
16
19
654
6682
30
173
617
6288
74
496
471
4977
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
9.9e-01
4.8e-01
—
—
—
1.9e+00
1.2e+00
cases:6.99%
controls:2.73%
cases:1.49%
controls:0.92%
—
—
—
—
—
—
cases:3.86%
controls:0.59%
cases:6.42%
controls:2.12%
47
183
625
6532
10
62
662
6653
—
—
—
25
38
622
6423
35
116
510
5357
Urology
34 [38004474]
34 [38004474]
8.9e-01
1.0e+00
—
—
—
1.1e+00
1.0e+00
cases:4.61%
controls:1.95%
cases:2.68%
controls:0.97%
—
—
—
—
—
—
cases:2.47%
controls:0.87%
cases:6.61%
controls:2.45%
31
131
641
6584
18
65
654
6650
—
—
—
16
56
631
6405
36
134
509
5339
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
6.6e-01
1.0e+00
1.3e+00
—
7.0e-01
1.4e+00
8.6e-01
cases:6.85%
controls:3.65%
cases:4.17%
controls:1.52%
cases:0.89%
controls:0.24%
—
—
cases:0.75%
controls:0.37%
cases:4.02%
controls:1.01%
cases:7.71%
controls:3.42%
46
245
626
6470
28
102
644
6613
6
16
666
6699
—
5
25
665
6676
26
65
621
6396
42
187
503
5286
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
6.0e-01
1.2e+00
9.2e-01
1.0e+50
5.5e-01
1.1e+00
1.1e+00
cases:13.39%
controls:7.85%
cases:6.85%
controls:2.14%
cases:0.89%
controls:0.36%
cases:1.04%
controls:0.00%
cases:0.75%
controls:0.43%
cases:5.41%
controls:1.95%
cases:14.86%
controls:5.76%
90
527
582
6188
46
144
626
6571
6
24
666
6691
7
0
665
6715
5
29
665
6672
35
126
612
6335
81
315
464
5158
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-6.2e-01
-6.7e-01
3.0e-01
—
—
2.5e+00
2.6e+00
cases:17.41%
controls:28.24%
cases:4.91%
controls:9.20%
cases:1.34%
controls:1.00%
—
—
—
—
cases:7.88%
controls:0.67%
cases:19.27%
controls:1.72%
117
1896
555
4819
33
618
639
6097
9
67
663
6648
—
—
51
43
596
6418
105
94
440
5379
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
4.5e-01
1.0e+00
—
—
2.2e+00
7.1e-01
6.6e-01
cases:9.52%
controls:6.31%
cases:4.61%
controls:1.68%
—
—
—
—
cases:0.90%
controls:0.10%
cases:2.78%
controls:1.39%
cases:8.44%
controls:4.55%
64
424
608
6291
31
113
641
6602
—
—
6
7
664
6694
18
90
629
6371
46
249
499
5224
hydroxychloroquine; oral
P01BA02 [21604889]
P01BA02 [21604889]
9.4e-01
8.3e-01
—
—
9.6e-01
1.0e+00
1.0e+00
cases:4.46%
controls:1.79%
cases:3.27%
controls:1.46%
—
—
—
—
cases:0.90%
controls:0.34%
cases:3.55%
controls:1.30%
cases:4.95%
controls:1.81%
30
120
642
6595
22
98
650
6617
—
—
6
23
664
6678
23
84
624
6377
27
99
518
5374
Cystoscopy
UKC02 [2001306005]
UKC02 [2001306005]
1.1e+00
1.5e+00
—
—
—
1.5e+00
1.3e+00
cases:3.13%
controls:1.10%
cases:1.79%
controls:0.40%
—
—
—
—
—
—
cases:1.39%
controls:0.33%
cases:3.30%
controls:0.97%
21
74
651
6641
12
27
660
6688
—
—
—
9
21
638
6440
18
53
527
5420
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
4.0e-01
6.2e-01
—
1.0e+50
—
2.5e+00
1.2e+00
cases:4.17%
controls:2.83%
cases:2.08%
controls:1.13%
—
—
cases:3.13%
controls:0.00%
—
—
cases:7.73%
controls:0.65%
cases:8.44%
controls:2.58%
28
190
644
6525
14
76
658
6639
—
21
0
651
6715
—
50
42
597
6419
46
141
499
5332
Destruction of lesion of skin, site unspecified
QXA25 [2001310041]
QXA25 [2001310041]
1.9e+00
—
—
—
—
2.1e+00
1.8e+00
cases:1.34%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.77%
controls:0.09%
cases:2.02%
controls:0.33%
9
14
663
6701
—
—
—
—
5
6
642
6455
11
18
534
5455
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
1.1e+00
8.4e-01
—
—
-1.0e+50
1.6e+00
9.3e-01
cases:3.42%
controls:1.12%
cases:0.89%
controls:0.39%
—
—
—
—
cases:0.00%
controls:0.09%
cases:1.55%
controls:0.31%
cases:3.49%
controls:1.41%
23
75
649
6640
6
26
666
6689
—
—
0
6
670
6695
10
20
637
6441
19
77
526
5396
Other specified urinary incontinence
N39.4 [45577525]
N39.4 [45577525]
4.2e-01
1.1e+00
—
—
—
1.4e+00
1.1e+00
cases:2.68%
controls:1.77%
cases:2.23%
controls:0.74%
—
—
—
—
—
—
cases:2.32%
controls:0.56%
cases:6.42%
controls:2.23%
18
119
654
6596
15
50
657
6665
—
—
—
15
36
632
6425
35
122
510
5351
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
33863-2 [3030366]
2.0e+00
1.6e+00
—
—
—
1.4e+00
8.8e-01
cases:2.08%
controls:0.28%
cases:1.19%
controls:0.24%
—
—
—
—
—
—
cases:1.08%
controls:0.26%
cases:1.65%
controls:0.69%
14
19
658
6696
8
16
664
6699
—
—
—
7
17
640
6444
9
38
536
5435
Lumbar epidural anesthesia
WX306 [2001310796]
WX306 [2001310796]
—
—
—
—
—
2.2e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.24%
controls:0.14%
cases:2.20%
controls:0.55%
—
—
—
—
—
8
9
639
6452
12
30
533
5443
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
7.9e-01
9.5e-01
—
—
—
1.0e+00
7.8e-01
cases:4.76%
controls:2.22%
cases:3.27%
controls:1.30%
—
—
—
—
—
—
cases:3.25%
controls:1.16%
cases:6.61%
controls:3.14%
32
149
640
6566
22
87
650
6628
—
—
—
21
75
626
6386
36
172
509
5301
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
1.3e+00
9.7e-01
—
—
—
1.2e+00
1.1e+00
cases:3.57%
controls:1.03%
cases:1.79%
controls:0.69%
—
—
—
—
—
—
cases:2.16%
controls:0.67%
cases:5.50%
controls:1.94%
24
69
648
6646
12
46
660
6669
—
—
—
14
43
633
6418
30
106
515
5367
Mouth breathing
R06.5 [45573006]
R06.5 [45573006]
1.4e+00
2.0e+00
—
—
—
—
—
cases:1.49%
controls:0.36%
cases:1.04%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
10
24
662
6691
7
10
665
6705
—
—
—
—
—
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
2.2e-01
1.6e-01
—
1.0e+50
—
2.1e+00
1.3e+00
cases:4.32%
controls:3.48%
cases:1.19%
controls:1.01%
—
—
cases:1.19%
controls:0.00%
—
—
cases:4.02%
controls:0.53%
cases:4.95%
controls:1.37%
29
234
643
6481
8
68
664
6647
—
8
0
664
6715
—
26
34
621
6427
27
75
518
5398
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
5.0e-01
6.0e-01
1.0e+00
—
5.7e-01
7.1e-01
5.2e-01
cases:28.27%
controls:19.29%
cases:17.26%
controls:10.28%
cases:3.57%
controls:1.33%
—
—
cases:2.24%
controls:1.28%
cases:19.17%
controls:10.40%
cases:34.86%
controls:24.12%
190
1295
482
5420
116
690
556
6025
24
89
648
6626
—
15
86
655
6615
124
672
523
5789
190
1320
355
4153
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
34548-8 [3045783]
7.1e-02
5.0e-01
1.8e+00
—
1.5e+00
5.3e-01
6.1e-01
cases:4.02%
controls:3.75%
cases:2.83%
controls:1.74%
cases:1.64%
controls:0.27%
—
—
cases:1.34%
controls:0.30%
cases:2.94%
controls:1.75%
cases:5.69%
controls:3.16%
27
252
645
6463
19
117
653
6598
11
18
661
6697
—
9
20
661
6681
19
113
628
6348
31
173
514
5300
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
1.9e-01
3.0e-01
2.8e-01
1.9e+00
6.9e-01
3.9e-01
1.7e-01
cases:43.15%
controls:38.59%
cases:35.86%
controls:29.31%
cases:6.55%
controls:5.05%
cases:1.64%
controls:0.24%
cases:9.10%
controls:4.79%
cases:37.25%
controls:28.73%
cases:55.23%
controls:51.09%
290
2591
382
4124
241
1968
431
4747
44
339
628
6376
11
16
661
6699
61
321
609
6380
241
1856
406
4605
301
2796
244
2677
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
4.2e-01
6.3e-01
6.6e-01
—
1.2e+00
7.0e-01
3.6e-01
cases:29.02%
controls:21.10%
cases:14.73%
controls:8.41%
cases:1.93%
controls:1.01%
—
—
cases:3.28%
controls:1.01%
cases:13.76%
controls:7.35%
cases:28.99%
controls:22.15%
195
1417
477
5298
99
565
573
6150
13
68
659
6647
—
22
68
648
6633
89
475
558
5986
158
1212
387
4261
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
9.7e-02
1.1e-01
5.0e-01
2.4e+00
8.9e-01
2.2e-01
2.7e-03
cases:34.23%
controls:32.08%
cases:27.23%
controls:25.09%
cases:8.18%
controls:5.15%
cases:2.08%
controls:0.19%
cases:11.49%
controls:5.04%
cases:29.83%
controls:25.43%
cases:41.65%
controls:41.59%
230
2154
442
4561
183
1685
489
5030
55
346
617
6369
14
13
658
6702
77
338
593
6363
193
1643
454
4818
227
2276
318
3197
Internal Medicine
11 [38004456]
11 [38004456]
4.7e-01
6.2e-01
9.4e-01
—
7.6e-01
5.2e-01
6.7e-01
cases:27.98%
controls:19.49%
cases:13.39%
controls:7.70%
cases:3.72%
controls:1.49%
—
—
cases:2.54%
controls:1.21%
cases:12.52%
controls:7.82%
cases:30.28%
controls:18.18%
188
1309
484
5406
90
517
582
6198
25
100
647
6615
—
17
81
653
6620
81
505
566
5956
165
995
380
4478
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
3.8e-01
4.4e-01
9.6e-01
—
8.2e-01
8.3e-01
5.2e-01
cases:13.99%
controls:9.99%
cases:8.48%
controls:5.63%
cases:3.27%
controls:1.28%
—
—
cases:3.28%
controls:1.48%
cases:11.44%
controls:5.34%
cases:20.18%
controls:13.03%
94
671
578
6044
57
378
615
6337
22
86
650
6629
—
22
99
648
6602
74
345
573
6116
110
713
435
4760
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
4.5e-01
5.6e-01
9.1e-01
-1.0e+50
8.0e-01
6.6e-01
4.8e-01
cases:26.34%
controls:18.56%
cases:15.92%
controls:9.77%
cases:2.98%
controls:1.22%
cases:0.00%
controls:0.07%
cases:2.99%
controls:1.36%
cases:17.77%
controls:10.08%
cases:33.76%
controls:24.05%
177
1246
495
5469
107
656
565
6059
20
82
652
6633
0
5
672
6710
20
91
650
6610
115
651
532
5810
184
1316
361
4157
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
3.0e-01
1.8e-01
—
1.0e+50
2.3e+00
1.7e+00
1.3e+00
cases:5.06%
controls:3.81%
cases:1.34%
controls:1.12%
—
—
cases:0.74%
controls:0.00%
cases:0.75%
controls:0.07%
cases:2.78%
controls:0.51%
cases:5.69%
controls:1.59%
34
256
638
6459
9
75
663
6640
—
5
0
667
6715
5
5
665
6696
18
33
629
6428
31
87
514
5386
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
3.5e-01
2.8e-01
8.5e-01
—
1.1e+00
5.9e-01
4.6e-01
cases:14.43%
controls:10.62%
cases:11.16%
controls:8.64%
cases:4.17%
controls:1.83%
—
—
cases:4.78%
controls:1.58%
cases:13.76%
controls:8.16%
cases:23.67%
controls:16.33%
97
713
575
6002
75
580
597
6135
28
123
644
6592
—
32
106
638
6595
89
527
558
5934
129
894
416
4579
Biopsy of endometrium
LCA06 [2001306551]
LCA06 [2001306551]
4.3e-01
7.2e-01
2.1e+00
1.0e+50
—
1.7e+00
1.4e+00
cases:2.98%
controls:1.95%
cases:1.49%
controls:0.73%
cases:0.74%
controls:0.09%
cases:1.34%
controls:0.00%
—
—
cases:2.63%
controls:0.51%
cases:6.97%
controls:1.88%
20
131
652
6584
10
49
662
6666
5
6
667
6709
9
0
663
6715
—
17
33
630
6428
38
103
507
5370
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
3.9e-01
5.5e-01
1.4e+00
—
2.3e+00
7.6e-01
2.8e-01
cases:7.14%
controls:4.93%
cases:4.76%
controls:2.81%
cases:1.34%
controls:0.33%
—
—
cases:2.24%
controls:0.24%
cases:6.96%
controls:3.39%
cases:12.48%
controls:9.70%
48
331
624
6384
32
189
640
6526
9
22
663
6693
—
15
16
655
6685
45
219
602
6242
68
531
477
4942
Rheumatology
66 [38004491]
66 [38004491]
7.9e-01
7.2e-01
1.1e+00
—
8.5e-01
8.1e-01
6.8e-01
cases:8.18%
controls:3.90%
cases:4.91%
controls:2.44%
cases:1.49%
controls:0.49%
—
—
cases:1.49%
controls:0.64%
cases:4.79%
controls:2.18%
cases:8.07%
controls:4.26%
55
262
617
6453
33
164
639
6551
10
33
662
6682
—
10
43
660
6658
31
141
616
6320
44
233
501
5240
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
6.5e-01
7.7e-01
—
—
1.2e+00
7.2e-01
8.2e-01
cases:13.99%
controls:7.83%
cases:6.25%
controls:3.01%
—
—
—
—
cases:0.75%
controls:0.22%
cases:5.87%
controls:2.94%
cases:17.61%
controls:8.61%
94
526
578
6189
42
202
630
6513
—
—
5
15
665
6686
38
190
609
6271
96
471
449
5002
Adjuvant radiotherapy
WF003 [2001310702]
WF003 [2001310702]
9.6e-01
—
—
—
—
2.9e+00
—
cases:1.04%
controls:0.40%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.11%
—
—
7
27
665
6688
—
—
—
—
13
7
634
6454
—
Supraglottic ventilation device
WX702 [2001310818]
WX702 [2001310818]
—
—
—
1.0e+50
—
2.9e+00
1.2e+00
—
—
—
—
—
—
cases:1.04%
controls:0.00%
—
—
cases:2.01%
controls:0.11%
cases:2.02%
controls:0.60%
—
—
—
7
0
665
6715
—
13
7
634
6454
11
33
534
5440
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
7.2e-01
9.6e-01
8.7e-01
—
6.3e-01
7.5e-01
4.9e-01
cases:21.28%
controls:11.66%
cases:9.67%
controls:3.93%
cases:1.34%
controls:0.57%
—
—
cases:0.90%
controls:0.48%
cases:6.49%
controls:3.17%
cases:17.61%
controls:11.55%
143
783
529
5932
65
264
607
6451
9
38
663
6677
—
6
32
664
6669
42
205
605
6256
96
632
449
4841
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
7.2e-01
9.6e-01
8.7e-01
—
6.3e-01
7.5e-01
4.9e-01
cases:21.28%
controls:11.66%
cases:9.67%
controls:3.93%
cases:1.34%
controls:0.57%
—
—
cases:0.90%
controls:0.48%
cases:6.49%
controls:3.17%
cases:17.61%
controls:11.55%
143
783
529
5932
65
264
607
6451
9
38
663
6677
—
6
32
664
6669
42
205
605
6256
96
632
449
4841
Kidney transplant status
Z94.0 [45566477]
Z94.0 [45566477]
—
—
—
1.0e+50
—
—
2.9e+00
—
—
—
—
—
—
cases:0.89%
controls:0.00%
—
—
—
—
cases:1.65%
controls:0.09%
—
—
—
6
0
666
6715
—
—
9
5
536
5468
Simple adjuvant cytostatic therapy
WB103 [2001310627]
WB103 [2001310627]
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.08%
—
—
—
—
—
—
—
9
5
638
6456
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
5.3e-01
1.4e+00
-1.0e+50
—
1.4e+00
9.8e-01
5.2e-01
cases:8.18%
controls:4.97%
cases:4.76%
controls:1.25%
cases:0.00%
controls:0.24%
—
—
cases:0.90%
controls:0.22%
cases:3.86%
controls:1.49%
cases:6.79%
controls:4.15%
55
334
617
6381
32
84
640
6631
0
16
672
6699
—
6
15
664
6686
25
96
622
6365
37
227
508
5246
Skin Pathology biopsy report
65754-4 [40768443]
65754-4 [40768443]
5.3e-01
1.8e+00
1.0e+50
—
—
1.1e+00
1.0e+00
cases:1.64%
controls:0.97%
cases:1.79%
controls:0.31%
cases:1.19%
controls:0.00%
—
—
—
—
cases:1.08%
controls:0.36%
cases:3.30%
controls:1.19%
11
65
661
6650
12
21
660
6694
8
0
664
6715
—
—
7
23
640
6438
18
65
527
5408
mirabegron; oral
G04BD12 [43534790]
G04BD12 [43534790]
7.5e-01
7.5e-01
1.2e+00
—
8.8e-01
1.0e+00
1.0e+00
cases:4.46%
controls:2.16%
cases:2.98%
controls:1.43%
cases:1.34%
controls:0.42%
—
—
cases:0.90%
controls:0.37%
cases:3.55%
controls:1.33%
cases:7.34%
controls:2.80%
30
145
642
6570
20
96
652
6619
9
28
663
6687
—
6
25
664
6676
23
86
624
6375
40
153
505
5320
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
3.5e-01
3.1e-01
3.3e-01
—
8.4e-01
7.0e-01
4.8e-01
cases:47.47%
controls:39.00%
cases:26.93%
controls:21.34%
cases:5.95%
controls:4.35%
—
—
cases:8.96%
controls:4.09%
cases:36.32%
controls:21.99%
cases:56.33%
controls:44.29%
319
2619
353
4096
181
1433
491
5282
40
292
632
6423
—
60
274
610
6427
235
1421
412
5040
307
2424
238
3049
itraconazole; oral, parenteral
J02AC02 [21603081]
J02AC02 [21603081]
8.3e-01
1.8e+00
—
—
—
1.4e+00
6.1e-01
cases:3.72%
controls:1.65%
cases:1.93%
controls:0.31%
—
—
—
—
—
—
cases:1.24%
controls:0.29%
cases:2.57%
controls:1.41%
25
111
647
6604
13
21
659
6694
—
—
—
8
19
639
6442
14
77
531
5396
Follow-up examination after surgery for malignant neoplasm
Z08.0 [45556811]
Z08.0 [45556811]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.09%
—
—
—
—
—
—
7
5
538
5468
hydrocortisone
S02BA01 [21605166]
S02BA01 [21605166]
6.8e-01
1.1e+00
1.3e+00
—
—
5.8e-01
8.2e-01
cases:13.10%
controls:7.12%
cases:6.99%
controls:2.34%
cases:0.89%
controls:0.25%
—
—
—
—
cases:3.55%
controls:2.03%
cases:13.21%
controls:6.29%
88
478
584
6237
47
157
625
6558
6
17
666
6698
—
—
23
131
624
6330
72
344
473
5129
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
6.7e-01
1.2e+00
1.2e+00
—
—
6.1e-01
7.7e-01
cases:15.03%
controls:8.28%
cases:8.18%
controls:2.71%
cases:0.89%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.32%
cases:14.68%
controls:7.35%
101
556
571
6159
55
182
617
6533
6
18
666
6697
—
—
27
150
620
6311
80
402
465
5071
hydrocortisone butyrate
D07AB02 [21602106]
D07AB02 [21602106]
6.7e-01
1.2e+00
1.2e+00
—
—
6.1e-01
7.7e-01
cases:15.03%
controls:8.28%
cases:8.18%
controls:2.71%
cases:0.89%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.32%
cases:14.68%
controls:7.35%
101
556
571
6159
55
182
617
6533
6
18
666
6697
—
—
27
150
620
6311
80
402
465
5071
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
6.7e-01
1.2e+00
1.2e+00
—
—
6.1e-01
7.7e-01
cases:15.03%
controls:8.28%
cases:8.18%
controls:2.71%
cases:0.89%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.32%
cases:14.68%
controls:7.35%
101
556
571
6159
55
182
617
6533
6
18
666
6697
—
—
27
150
620
6311
80
402
465
5071
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
6.7e-01
1.2e+00
1.2e+00
—
—
6.1e-01
7.7e-01
cases:15.03%
controls:8.28%
cases:8.18%
controls:2.71%
cases:0.89%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.32%
cases:14.68%
controls:7.35%
101
556
571
6159
55
182
617
6533
6
18
666
6697
—
—
27
150
620
6311
80
402
465
5071
Disruption of operation wound, not elsewhere classified
T81.3 [45556234]
T81.3 [45556234]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.11%
—
—
—
—
—
—
8
6
537
5467
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
3.3e-01
6.0e-01
2.2e-01
—
1.5e+00
5.5e-01
3.6e-01
cases:12.35%
controls:9.19%
cases:7.89%
controls:4.48%
cases:0.74%
controls:0.60%
—
—
cases:1.64%
controls:0.39%
cases:8.50%
controls:5.09%
cases:20.00%
controls:14.91%
83
617
589
6098
53
301
619
6414
5
40
667
6675
—
11
26
659
6675
55
329
592
6132
109
816
436
4657
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
6.6e-01
1.2e+00
1.4e+00
—
—
5.9e-01
7.6e-01
cases:15.03%
controls:8.34%
cases:8.18%
controls:2.73%
cases:1.04%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.37%
cases:14.68%
controls:7.44%
101
560
571
6155
55
183
617
6532
7
18
665
6697
—
—
27
153
620
6308
80
407
465
5066
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
6.6e-01
1.2e+00
1.4e+00
—
—
5.9e-01
7.6e-01
cases:15.03%
controls:8.34%
cases:8.18%
controls:2.73%
cases:1.04%
controls:0.27%
—
—
—
—
cases:4.17%
controls:2.37%
cases:14.68%
controls:7.44%
101
560
571
6155
55
183
617
6532
7
18
665
6697
—
—
27
153
620
6308
80
407
465
5066
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
1.2e-01
2.7e-01
1.3e+00
—
—
1.7e+00
8.4e-01
cases:5.21%
controls:4.65%
cases:2.68%
controls:2.06%
cases:0.89%
controls:0.25%
—
—
—
—
cases:8.50%
controls:1.72%
cases:11.93%
controls:5.52%
35
312
637
6403
18
138
654
6577
6
17
666
6698
—
—
55
111
592
6350
65
302
480
5171
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1754-1 [3012516]
5.9e-01
6.7e-01
7.7e-01
—
1.1e+00
6.8e-01
5.7e-01
cases:11.90%
controls:7.00%
cases:8.78%
controls:4.71%
cases:0.89%
controls:0.42%
—
—
cases:0.90%
controls:0.30%
cases:8.35%
controls:4.40%
cases:18.53%
controls:11.38%
80
470
592
6245
59
316
613
6399
6
28
666
6687
—
6
20
664
6681
54
284
593
6177
101
623
444
4850
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
7.6e-01
9.1e-01
1.9e+00
—
—
1.3e+00
1.2e+00
cases:3.57%
controls:1.70%
cases:2.08%
controls:0.85%
cases:0.89%
controls:0.13%
—
—
—
—
cases:2.32%
controls:0.62%
cases:5.69%
controls:1.85%
24
114
648
6601
14
57
658
6658
6
9
666
6706
—
—
15
40
632
6421
31
101
514
5372
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
2.6e-01
7.2e-01
2.5e+00
—
—
8.2e-01
4.0e-01
cases:5.06%
controls:3.96%
cases:2.23%
controls:1.10%
cases:0.89%
controls:0.07%
—
—
—
—
cases:2.01%
controls:0.90%
cases:5.69%
controls:3.87%
34
266
638
6449
15
74
657
6641
6
5
666
6710
—
—
13
58
634
6403
31
212
514
5261
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
9.0e-01
1.3e+00
-1.0e+50
—
—
—
1.6e+00
cases:2.98%
controls:1.24%
cases:1.19%
controls:0.33%
cases:0.00%
controls:0.07%
—
—
—
—
—
—
cases:4.40%
controls:0.95%
20
83
652
6632
8
22
664
6693
0
5
672
6710
—
—
—
24
52
521
5421
Other and unspecified ovarian cysts
N83.2 [45539066]
N83.2 [45539066]
3.5e-01
1.1e+00
—
1.0e+50
—
1.3e+00
6.4e-01
cases:2.53%
controls:1.80%
cases:1.93%
controls:0.64%
—
—
cases:1.34%
controls:0.00%
—
—
cases:1.85%
controls:0.50%
cases:3.12%
controls:1.66%
17
121
655
6594
13
43
659
6672
—
9
0
663
6715
—
12
32
635
6429
17
91
528
5382
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
1.1e-01
—
—
—
—
2.4e+00
6.2e-01
cases:1.79%
controls:1.61%
—
—
—
—
—
—
—
—
cases:1.24%
controls:0.11%
cases:1.28%
controls:0.69%
12
108
660
6607
—
—
—
—
8
7
639
6454
7
38
538
5435
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
6.2e-01
6.4e-01
4.5e-01
—
1.0e+00
6.0e-01
5.8e-01
cases:12.95%
controls:7.42%
cases:8.78%
controls:4.84%
cases:0.74%
controls:0.48%
—
—
cases:0.90%
controls:0.33%
cases:8.04%
controls:4.57%
cases:19.27%
controls:11.77%
87
498
585
6217
59
325
613
6390
5
32
667
6683
—
6
22
664
6679
52
295
595
6166
105
644
440
4829
Other lichen planus
L43.8 [45577038]
L43.8 [45577038]
1.5e+00
—
—
1.0e+50
—
—
2.4e+00
cases:0.74%
controls:0.16%
—
—
—
—
cases:0.74%
controls:0.00%
—
—
—
—
cases:1.65%
controls:0.15%
5
11
667
6704
—
—
5
0
667
6715
—
—
9
8
536
5465
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
5.3e-01
7.6e-01
—
—
8.2e-01
5.7e-01
5.6e-01
cases:12.05%
controls:7.46%
cases:7.89%
controls:3.84%
—
—
—
—
cases:1.04%
controls:0.46%
cases:7.57%
controls:4.41%
cases:19.45%
controls:12.13%
81
501
591
6214
53
258
619
6457
—
—
7
31
663
6670
49
285
598
6176
106
664
439
4809
Excision of lesion of vulva or perineum
LFB10 [2001306760]
LFB10 [2001306760]
2.4e+00
—
1.0e+50
1.0e+50
1.0e+50
—
—
cases:1.49%
controls:0.13%
—
—
cases:1.04%
controls:0.00%
cases:11.61%
controls:0.00%
cases:6.27%
controls:0.00%
—
—
—
—
10
9
662
6706
—
7
0
665
6715
78
0
594
6715
42
0
628
6701
—
—
Irritable bowel syndrome
K58 [45572218]
K58 [45572218]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.65%
controls:0.16%
—
—
—
—
—
—
9
9
536
5464
Addiction caused by tobacco UNS
F17.29 [2000501845]
F17.29 [2000501845]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.13%
—
—
—
—
—
—
7
7
538
5466
Flap of skin
ZZR00 [2001311677]
ZZR00 [2001311677]
—
—
—
—
—
1.0e+50
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:0.77%
controls:0.00%
cases:1.28%
controls:0.13%
—
—
—
—
—
5
0
642
6461
7
7
538
5466
Liver Pathology biopsy report
65752-8 [40768441]
65752-8 [40768441]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.11%
—
—
—
—
—
—
6
6
539
5467
Extensive MRI examination of lower part of abdoment with high intensity magnet
JN2CG [2001305544]
JN2CG [2001305544]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.11%
—
—
—
—
—
—
6
6
539
5467
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
5.4e-01
5.8e-01
5.7e-01
—
9.2e-01
6.3e-01
5.2e-01
cases:12.50%
controls:7.65%
cases:8.78%
controls:5.12%
cases:0.89%
controls:0.51%
—
—
cases:0.90%
controls:0.36%
cases:8.66%
controls:4.78%
cases:18.72%
controls:12.04%
84
514
588
6201
59
344
613
6371
6
34
666
6681
—
6
24
664
6677
56
309
591
6152
102
659
443
4814
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
UJF45 [2001305031]
6.6e-01
2.2e+00
—
—
—
—
5.5e-01
cases:1.49%
controls:0.77%
cases:1.64%
controls:0.18%
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.64%
10
52
662
6663
11
12
661
6703
—
—
—
—
6
35
539
5438
Laceration/cut
S18 [2002000983]
S18 [2002000983]
1.1e-01
6.3e-01
9.2e-01
—
1.6e+00
6.2e-01
2.2e-01
cases:9.38%
controls:8.47%
cases:5.65%
controls:3.10%
cases:1.34%
controls:0.54%
—
—
cases:2.24%
controls:0.46%
cases:5.41%
controls:2.99%
cases:12.29%
controls:10.07%
63
569
609
6146
38
208
634
6507
9
36
663
6679
—
15
31
655
6670
35
193
612
6268
67
551
478
4922
Thorax extensive CT-examination
GD1BD [2001303621]
GD1BD [2001303621]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.16%
—
—
—
—
—
—
8
9
537
5464
Other minor surgical procedure in gynaecology
TLW99 [2001306821]
TLW99 [2001306821]
1.1e+00
—
—
—
—
—
2.2e+00
cases:0.74%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.16%
5
16
667
6699
—
—
—
—
—
8
9
537
5464
Sentinel node biopsy
PJA12 [2001309627]
PJA12 [2001309627]
3.7e-01
9.5e-01
—
—
—
2.2e+00
8.0e-01
cases:1.64%
controls:1.13%
cases:1.34%
controls:0.52%
—
—
—
—
—
—
cases:1.85%
controls:0.22%
cases:1.65%
controls:0.75%
11
76
661
6639
9
35
663
6680
—
—
—
12
14
635
6447
9
41
536
5432
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
2.7e-01
1.8e-01
4.8e-01
—
1.1e+00
6.4e-01
3.8e-01
cases:43.60%
controls:37.19%
cases:19.94%
controls:17.19%
cases:3.57%
controls:2.23%
—
—
cases:7.46%
controls:2.51%
cases:27.20%
controls:16.45%
cases:44.04%
controls:35.03%
293
2497
379
4218
134
1154
538
5561
24
150
648
6565
—
50
168
620
6533
176
1063
471
5398
240
1917
305
3556
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
2.7e-01
1.8e-01
4.8e-01
—
1.1e+00
6.4e-01
3.8e-01
cases:43.60%
controls:37.19%
cases:19.94%
controls:17.19%
cases:3.57%
controls:2.23%
—
—
cases:7.46%
controls:2.51%
cases:27.20%
controls:16.45%
cases:44.04%
controls:35.03%
293
2497
379
4218
134
1154
538
5561
24
150
648
6565
—
50
168
620
6533
176
1063
471
5398
240
1917
305
3556
Noninflammatory disorder of vulva and perineum, unspecified
N90.9 [45534147]
N90.9 [45534147]
—
—
1.0e+50
—
—
1.0e+50
2.2e+00
—
—
—
—
cases:0.74%
controls:0.00%
—
—
—
—
cases:0.77%
controls:0.00%
cases:1.10%
controls:0.13%
—
—
5
0
667
6715
—
—
5
0
642
6461
6
7
539
5466
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
3.4e-01
2.4e-01
8.4e-01
—
9.7e-01
3.8e-01
3.1e-01
cases:22.62%
controls:17.17%
cases:10.86%
controls:8.74%
cases:3.13%
controls:1.37%
—
—
cases:4.03%
controls:1.57%
cases:13.29%
controls:9.49%
cases:28.44%
controls:22.53%
152
1153
520
5562
73
587
599
6128
21
92
651
6623
—
27
105
643
6596
86
613
561
5848
155
1233
390
4240
Lichen planus, unspecified
L43.9 [45591635]
L43.9 [45591635]
2.2e+00
—
—
—
—
—
1.6e+00
cases:0.89%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.22%
6
7
666
6708
—
—
—
—
—
6
12
539
5461
Pruritus
S02 [2002000967]
S02 [2002000967]
—
2.2e+00
—
—
—
—
—
—
—
cases:0.89%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
6
7
666
6708
—
—
—
—
—
Laparoscopic bilateral salpingo-oophorectomy
LAF11 [2001306444]
LAF11 [2001306444]
7.6e-01
—
—
—
—
2.2e+00
7.3e-01
cases:1.49%
controls:0.70%
—
—
—
—
—
—
—
—
cases:0.93%
controls:0.11%
cases:1.28%
controls:0.62%
10
47
662
6668
—
—
—
—
6
7
641
6454
7
34
538
5439
Squamous intraepithelial neoplasia, high grade of cervix uteri
8077/2-C53.9 [44501336]
8077/2-C53.9 [44501336]
2.1e+00
—
—
—
—
—
1.7e+00
cases:1.64%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:0.92%
controls:0.16%
11
13
661
6702
—
—
—
—
—
5
9
540
5464
Vaginal symptom/complaint other
X15 [2002001300]
X15 [2002001300]
7.0e-01
2.1e+00
—
—
—
—
—
cases:0.89%
controls:0.45%
cases:1.93%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
6
30
666
6685
13
16
659
6699
—
—
—
—
—
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
6.0e-01
8.9e-01
—
—
—
1.8e-01
6.1e-01
cases:11.90%
controls:6.92%
cases:5.65%
controls:2.40%
—
—
—
—
—
—
cases:3.09%
controls:2.58%
cases:12.84%
controls:7.42%
80
465
592
6250
38
161
634
6554
—
—
—
20
167
627
6294
70
406
475
5067
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
6.0e-01
8.9e-01
—
—
—
1.8e-01
6.1e-01
cases:11.90%
controls:6.92%
cases:5.65%
controls:2.40%
—
—
—
—
—
—
cases:3.09%
controls:2.58%
cases:12.84%
controls:7.42%
80
465
592
6250
38
161
634
6554
—
—
—
20
167
627
6294
70
406
475
5067
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
6.0e-01
8.9e-01
—
—
—
1.8e-01
6.1e-01
cases:11.90%
controls:6.92%
cases:5.65%
controls:2.40%
—
—
—
—
—
—
cases:3.09%
controls:2.58%
cases:12.84%
controls:7.42%
80
465
592
6250
38
161
634
6554
—
—
—
20
167
627
6294
70
406
475
5067
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
6.0e-01
8.9e-01
—
—
—
1.8e-01
6.1e-01
cases:11.90%
controls:6.92%
cases:5.65%
controls:2.40%
—
—
—
—
—
—
cases:3.09%
controls:2.58%
cases:12.84%
controls:7.42%
80
465
592
6250
38
161
634
6554
—
—
—
20
167
627
6294
70
406
475
5067
High dependency care
WX882 [2001310847]
WX882 [2001310847]
2.1e+00
—
—
—
—
—
-1.0e+50
cases:1.04%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
7
9
665
6706
—
—
—
—
—
0
7
545
5466
Protein [Mass/volume] in Urine
2888-6 [3037121]
2888-6 [3037121]
5.4e-01
2.1e+00
—
—
—
—
—
cases:1.04%
controls:0.61%
cases:1.04%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
7
41
665
6674
7
9
665
6706
—
—
—
—
—
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
T81.0 [45599741]
T81.0 [45599741]
5.1e-01
—
—
—
—
2.1e+00
7.0e-01
cases:0.89%
controls:0.54%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.14%
cases:1.28%
controls:0.64%
6
36
666
6679
—
—
—
—
7
9
640
6452
7
35
538
5438
Remowal of suture of skin
TQW40 [2001310146]
TQW40 [2001310146]
8.2e-01
—
—
—
—
2.1e+00
3.1e-01
cases:1.34%
controls:0.60%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.14%
cases:0.92%
controls:0.68%
9
40
663
6675
—
—
—
—
7
9
640
6452
5
37
540
5436
Sicca syndrome [Sjögren]
M35.0 [45562711]
M35.0 [45562711]
8.4e-01
1.6e+00
—
—
—
2.1e+00
9.7e-01
cases:0.89%
controls:0.39%
cases:1.04%
controls:0.21%
—
—
—
—
—
—
cases:1.08%
controls:0.14%
cases:1.10%
controls:0.42%
6
26
666
6689
7
14
665
6701
—
—
—
7
9
640
6452
6
23
539
5450
epinephrine
S01EA01 [21603673]
S01EA01 [21603673]
9.2e-01
1.0e+00
—
—
—
1.1e+00
1.1e+00
cases:2.98%
controls:1.21%
cases:1.19%
controls:0.43%
—
—
—
—
—
—
cases:1.39%
controls:0.46%
cases:2.57%
controls:0.84%
20
81
652
6634
8
29
664
6686
—
—
—
9
30
638
6431
14
46
531
5427
epinephrine; parenteral
C01CA24 [21600303]
C01CA24 [21600303]
9.2e-01
1.0e+00
—
—
—
1.1e+00
1.1e+00
cases:2.98%
controls:1.21%
cases:1.19%
controls:0.43%
—
—
—
—
—
—
cases:1.39%
controls:0.46%
cases:2.57%
controls:0.84%
20
81
652
6634
8
29
664
6686
—
—
—
9
30
638
6431
14
46
531
5427
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
4.2e-01
4.4e-01
4.7e-01
—
8.3e-01
6.5e-01
5.5e-01
cases:17.86%
controls:12.54%
cases:11.31%
controls:7.59%
cases:2.08%
controls:1.31%
—
—
cases:2.54%
controls:1.12%
cases:12.98%
controls:7.24%
cases:25.69%
controls:16.59%
120
842
552
5873
76
510
596
6205
14
88
658
6627
—
17
75
653
6626
84
468
563
5993
140
908
405
4565
Hematology
82 [38004501]
82 [38004501]
1.0e+00
1.0e+00
1.7e+00
—
1.3e+00
4.0e-01
7.3e-01
cases:3.13%
controls:1.16%
cases:2.08%
controls:0.74%
cases:0.89%
controls:0.16%
—
—
cases:0.75%
controls:0.21%
cases:1.24%
controls:0.84%
cases:2.75%
controls:1.35%
21
78
651
6637
14
50
658
6665
6
11
666
6704
—
5
14
665
6687
8
54
639
6407
15
74
530
5399
Ulceration of vulva
N76.6 [45558170]
N76.6 [45558170]
—
1.0e+50
—
1.0e+50
1.0e+50
—
2.0e+00
—
—
cases:3.42%
controls:0.00%
—
—
cases:0.89%
controls:0.00%
cases:0.90%
controls:0.00%
—
—
cases:1.10%
controls:0.15%
—
23
0
649
6715
—
6
0
666
6715
6
0
664
6701
—
6
8
539
5465
Cancers of female genital organs
128 [2001600126]
128 [2001600126]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.15%
—
—
—
—
—
—
6
8
539
5465
Pregnancy, not (yet) confirmed
Z32.0 [45585821]
Z32.0 [45585821]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.15%
—
—
—
—
—
—
6
8
539
5465
Radical radiotherapy
WF002 [2001310701]
WF002 [2001310701]
1.1e+00
—
—
—
—
1.0e+50
2.0e+00
cases:0.74%
controls:0.25%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.00%
cases:1.10%
controls:0.15%
5
17
667
6698
—
—
—
—
9
0
638
6461
6
8
539
5465
Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight
47845-3 [3048821]
47845-3 [3048821]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.15%
—
—
—
—
—
—
6
8
539
5465
Faecal incontinence
R15 [45573014]
R15 [45573014]
9.6e-01
2.0e+00
—
—
—
—
1.3e+00
cases:0.89%
controls:0.34%
cases:0.89%
controls:0.12%
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.35%
6
23
666
6692
6
8
666
6707
—
—
—
—
7
19
538
5454
Endometriosis, unspecified
N80.9 [45543892]
N80.9 [45543892]
2.0e+00
—
—
—
—
—
—
cases:0.89%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
666
6707
—
—
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
3.8e-01
5.9e-01
6.4e-01
—
9.7e-01
6.7e-01
3.6e-01
cases:15.63%
controls:11.26%
cases:11.01%
controls:6.43%
cases:1.49%
controls:0.79%
—
—
cases:1.79%
controls:0.69%
cases:13.29%
controls:7.31%
cases:25.87%
controls:19.66%
105
756
567
5959
74
432
598
6283
10
53
662
6662
—
12
46
658
6655
86
472
561
5989
141
1076
404
4397
Day surgery
ZXD20 [2001311388]
ZXD20 [2001311388]
2.0e-01
—
—
—
—
2.0e+00
6.4e-01
cases:1.34%
controls:1.10%
—
—
—
—
—
—
—
—
cases:1.55%
controls:0.22%
cases:1.65%
controls:0.88%
9
74
663
6641
—
—
—
—
10
14
637
6447
9
48
536
5425
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
6.2e-01
5.5e-01
—
—
—
6.5e-01
6.9e-01
cases:9.82%
controls:5.51%
cases:4.61%
controls:2.71%
—
—
—
—
—
—
cases:5.41%
controls:2.89%
cases:15.23%
controls:8.26%
66
370
606
6345
31
182
641
6533
—
—
—
35
187
612
6274
83
452
462
5021
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
7.0e-01
1.8e-01
—
—
—
1.3e+00
6.2e-01
cases:5.65%
controls:2.90%
cases:1.93%
controls:1.62%
—
—
—
—
—
—
cases:4.33%
controls:1.25%
cases:6.79%
controls:3.78%
38
195
634
6520
13
109
659
6606
—
—
—
28
81
619
6380
37
207
508
5266
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
J84.9 [45543277]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.18%
—
—
—
—
—
—
7
10
538
5463
pH of Blood
11558-4 [3010421]
11558-4 [3010421]
—
—
—
—
—
1.9e+00
7.9e-01
—
—
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.20%
cases:1.28%
controls:0.58%
—
—
—
—
—
9
13
638
6448
7
32
538
5441
Pruritus vulvae
L29.2 [45543369]
L29.2 [45543369]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.33%
—
—
—
—
—
—
12
18
533
5455
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
8.4e-01
4.8e-01
—
—
-1.0e+50
1.1e+00
5.9e-01
cases:5.36%
controls:2.38%
cases:1.34%
controls:0.83%
—
—
—
—
cases:0.00%
controls:0.13%
cases:2.01%
controls:0.70%
cases:4.04%
controls:2.28%
36
160
636
6555
9
56
663
6659
—
—
0
9
670
6692
13
45
634
6416
22
125
523
5348
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
SPAT1144 [2001700245]
5.3e-01
—
—
—
—
1.9e+00
2.5e-01
cases:1.64%
controls:0.97%
—
—
—
—
—
—
—
—
cases:1.55%
controls:0.23%
cases:0.92%
controls:0.71%
11
65
661
6650
—
—
—
—
10
15
637
6446
5
39
540
5434
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
5.6e-01
4.4e-01
-1.0e+50
—
1.8e+00
1.9e+00
4.5e-01
cases:4.46%
controls:2.61%
cases:1.79%
controls:1.16%
cases:0.00%
controls:0.10%
—
—
cases:0.75%
controls:0.12%
cases:3.86%
controls:0.60%
cases:5.14%
controls:3.34%
30
175
642
6540
12
78
660
6637
0
7
672
6708
—
5
8
665
6693
25
39
622
6422
28
183
517
5290
Other and unspecified skin changes
R23.8 [45573020]
R23.8 [45573020]
6.8e-01
1.2e+00
2.0e+00
—
—
7.7e-01
3.3e-01
cases:5.51%
controls:2.86%
cases:4.17%
controls:1.30%
cases:0.74%
controls:0.10%
—
—
—
—
cases:2.32%
controls:1.08%
cases:6.79%
controls:4.97%
37
192
635
6523
28
87
644
6628
5
7
667
6708
—
—
15
70
632
6391
37
272
508
5201
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
6357-8 [3024950]
9.5e-01
9.0e-01
1.6e+00
—
—
-1.4e-03
3.9e-01
cases:7.44%
controls:3.01%
cases:3.13%
controls:1.30%
cases:0.74%
controls:0.15%
—
—
—
—
cases:1.08%
controls:1.08%
cases:4.04%
controls:2.76%
50
202
622
6513
21
87
651
6628
5
10
667
6705
—
—
7
70
640
6391
22
151
523
5322
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
5.9e-01
7.5e-01
—
—
—
1.0e+00
8.1e-01
cases:3.57%
controls:2.01%
cases:2.08%
controls:1.00%
—
—
—
—
—
—
cases:2.78%
controls:1.01%
cases:4.59%
controls:2.10%
24
135
648
6580
14
67
658
6648
—
—
—
18
65
629
6396
25
115
520
5358
Cytology report of Urine Cyto stain
47525-1 [3049717]
47525-1 [3049717]
9.9e-01
—
—
—
—
—
1.8e+00
cases:1.19%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:2.75%
controls:0.46%
8
30
664
6685
—
—
—
—
—
15
25
530
5448
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
7.4e-01
1.1e+00
—
—
—
3.3e-01
5.6e-01
cases:6.25%
controls:3.08%
cases:3.27%
controls:1.15%
—
—
—
—
—
—
cases:1.55%
controls:1.11%
cases:6.61%
controls:3.89%
42
207
630
6508
22
77
650
6638
—
—
—
10
72
637
6389
36
213
509
5260
varenicline; oral
N07BA03 [21604819]
N07BA03 [21604819]
7.0e-01
1.8e+00
—
—
—
1.8e+00
1.8e+00
cases:1.19%
controls:0.60%
cases:0.89%
controls:0.15%
—
—
—
—
—
—
cases:0.77%
controls:0.12%
cases:1.65%
controls:0.27%
8
40
664
6675
6
10
666
6705
—
—
—
5
8
642
6453
9
15
536
5458
Operation for osteochondritis of knee, arthroscopic
NGF25 [2001308133]
NGF25 [2001308133]
1.0e+00
-1.0e+50
—
—
—
—
1.8e+00
cases:0.89%
controls:0.33%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.22%
6
22
666
6693
0
7
672
6708
—
—
—
—
7
12
538
5461
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
6.6e-01
3.2e-01
—
—
—
1.1e+00
6.3e-01
cases:3.72%
controls:1.95%
cases:1.19%
controls:0.86%
—
—
—
—
—
—
cases:3.09%
controls:1.01%
cases:6.61%
controls:3.62%
25
131
647
6584
8
58
664
6657
—
—
—
20
65
627
6396
36
198
509
5275
Electrophysiological investigation
TFP34 [2001303229]
TFP34 [2001303229]
1.8e+00
—
—
—
—
—
-1.0e+50
cases:1.04%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
7
12
665
6703
—
—
—
—
—
0
11
545
5462
alfacalcidol; oral, parenteral
A11CC03 [21600818]
A11CC03 [21600818]
1.8e+00
1.5e+00
—
—
—
1.4e+00
1.3e+00
cases:1.04%
controls:0.18%
cases:0.89%
controls:0.19%
—
—
—
—
—
—
cases:0.93%
controls:0.23%
cases:1.10%
controls:0.29%
7
12
665
6703
6
13
666
6702
—
—
—
6
15
641
6446
6
16
539
5457
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
5.9e-01
—
—
—
—
1.8e+00
1.2e+00
cases:2.23%
controls:1.25%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.19%
cases:2.20%
controls:0.68%
15
84
657
6631
—
—
—
—
7
12
640
6449
12
37
533
5436
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
8.6e-01
9.1e-01
—
—
—
7.9e-01
4.3e-01
cases:5.65%
controls:2.47%
cases:2.83%
controls:1.16%
—
—
—
—
—
—
cases:2.32%
controls:1.07%
cases:4.40%
controls:2.91%
38
166
634
6549
19
78
653
6637
—
—
—
15
69
632
6392
24
159
521
5314
Chronic respiratory failure
J96.1 [45557632]
J96.1 [45557632]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.26%
—
—
—
—
—
—
8
14
537
5459
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
8.5e-01
6.8e-01
—
—
-1.0e+50
7.2e-01
9.1e-01
cases:4.91%
controls:2.16%
cases:1.64%
controls:0.83%
—
—
—
—
cases:0.00%
controls:0.07%
cases:1.39%
controls:0.68%
cases:6.06%
controls:2.54%
33
145
639
6570
11
56
661
6659
—
—
0
5
670
6696
9
44
638
6417
33
139
512
5334
Diplopia
H53.2 [45576792]
H53.2 [45576792]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.65%
controls:0.29%
—
—
—
—
—
—
9
16
536
5457
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
6.0e-01
—
—
—
—
—
1.7e+00
cases:0.89%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:1.65%
controls:0.29%
6
33
666
6682
—
—
—
—
—
9
16
536
5457
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
3.2e-01
5.5e-01
1.2e+00
—
1.0e+00
7.9e-01
9.3e-01
cases:11.76%
controls:8.85%
cases:5.51%
controls:3.25%
cases:1.79%
controls:0.57%
—
—
cases:1.19%
controls:0.43%
cases:6.96%
controls:3.27%
cases:19.63%
controls:8.79%
79
594
593
6121
37
218
635
6497
12
38
660
6677
—
8
29
662
6672
45
211
602
6250
107
481
438
4992
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
D01AC20 [21601936]
6.6e-01
1.1e+00
—
—
—
5.8e-01
4.3e-01
cases:7.89%
controls:4.23%
cases:4.17%
controls:1.49%
—
—
—
—
—
—
cases:2.01%
controls:1.13%
cases:5.69%
controls:3.76%
53
284
619
6431
28
100
644
6615
—
—
—
13
73
634
6388
31
206
514
5267
Hip joint ultrasound examination
NF1AE [2001307895]
NF1AE [2001307895]
1.7e+00
—
—
—
—
—
—
cases:1.19%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
8
15
664
6700
—
—
—
—
—
—
Midwife
Z3232 [2001311563]
Z3232 [2001311563]
—
1.5e+00
—
—
—
1.7e+00
7.0e-01
—
—
cases:1.04%
controls:0.24%
—
—
—
—
—
—
cases:1.24%
controls:0.23%
cases:1.47%
controls:0.73%
—
7
16
665
6699
—
—
—
8
15
639
6446
8
40
537
5433
Unspecified haematuria
R31 [45553726]
R31 [45553726]
7.3e-01
—
—
—
—
—
1.7e+00
cases:1.04%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:2.57%
controls:0.49%
7
34
665
6681
—
—
—
—
—
14
27
531
5446
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
3.9e-01
4.6e-01
6.7e-01
—
6.1e-01
7.3e-01
5.5e-01
cases:16.82%
controls:11.99%
cases:8.18%
controls:5.33%
cases:1.93%
controls:1.00%
—
—
cases:1.79%
controls:0.98%
cases:10.20%
controls:5.20%
cases:18.53%
controls:11.64%
113
805
559
5910
55
358
617
6357
13
67
659
6648
—
12
66
658
6635
66
336
581
6125
101
637
444
4836
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
4.5e-01
4.6e-01
6.6e-01
—
8.7e-01
5.9e-01
6.1e-01
cases:11.90%
controls:7.91%
cases:7.59%
controls:4.93%
cases:1.49%
controls:0.77%
—
—
cases:1.79%
controls:0.76%
cases:8.35%
controls:4.80%
cases:17.25%
controls:10.20%
80
531
592
6184
51
331
621
6384
10
52
662
6663
—
12
51
658
6650
54
310
593
6151
94
558
451
4915
Knee X-ray examination without contrast
NG1AA [2001308049]
NG1AA [2001308049]
7.7e-01
4.2e-01
—
—
—
—
8.8e-01
cases:3.87%
controls:1.83%
cases:0.74%
controls:0.49%
—
—
—
—
—
—
—
—
cases:4.22%
controls:1.79%
26
123
646
6592
5
33
667
6682
—
—
—
—
23
98
522
5375
Otolaryngology
4 [38004449]
4 [38004449]
5.0e-01
4.8e-01
1.2e-01
-1.0e+50
5.2e-01
5.7e-01
5.8e-01
cases:17.11%
controls:11.15%
cases:6.70%
controls:4.24%
cases:0.89%
controls:0.79%
cases:0.00%
controls:0.07%
cases:1.19%
controls:0.72%
cases:6.80%
controls:3.95%
cases:18.72%
controls:11.44%
115
749
557
5966
45
285
627
6430
6
53
666
6662
0
5
672
6710
8
48
662
6653
44
255
603
6206
102
626
443
4847
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
3.8e-01
4.6e-01
6.7e-01
—
6.1e-01
7.2e-01
5.5e-01
cases:16.52%
controls:11.94%
cases:8.18%
controls:5.33%
cases:1.93%
controls:1.00%
—
—
cases:1.79%
controls:0.98%
cases:10.05%
controls:5.17%
cases:18.53%
controls:11.58%
111
802
561
5913
55
358
617
6357
13
67
659
6648
—
12
66
658
6635
65
334
582
6127
101
634
444
4839
Other minor procedure on skin
TQW99 [2001310150]
TQW99 [2001310150]
1.2e+00
—
—
—
—
—
1.6e+00
cases:1.04%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:2.75%
controls:0.55%
7
22
665
6693
—
—
—
—
—
15
30
530
5443
tizanidine; oral
M03BX02 [21604116]
M03BX02 [21604116]
3.8e-01
6.1e-01
5.1e-01
—
9.2e-01
1.7e-01
6.4e-01
cases:18.45%
controls:13.39%
cases:8.18%
controls:4.63%
cases:0.89%
controls:0.54%
—
—
cases:1.34%
controls:0.54%
cases:5.56%
controls:4.72%
cases:21.28%
controls:12.44%
124
899
548
5816
55
311
617
6404
6
36
666
6679
—
9
36
661
6665
36
305
611
6156
116
681
429
4792
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
4.3e-01
4.2e-01
4.8e-01
—
8.3e-01
6.5e-01
5.5e-01
cases:18.01%
controls:12.51%
cases:11.16%
controls:7.61%
cases:2.08%
controls:1.30%
—
—
cases:2.54%
controls:1.12%
cases:12.98%
controls:7.21%
cases:25.69%
controls:16.63%
121
840
551
5875
75
511
597
6204
14
87
658
6628
—
17
75
653
6626
84
466
563
5995
140
910
405
4563
Local dermatologic skincare
TQW80 [2001310149]
TQW80 [2001310149]
7.4e-01
—
—
—
—
—
1.6e+00
cases:0.74%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:1.65%
controls:0.33%
5
24
667
6691
—
—
—
—
—
9
18
536
5455
Shoulder extensive X-ray examination without contrast
NB1BA [2001307228]
NB1BA [2001307228]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.29%
—
—
—
—
—
—
8
16
537
5457
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
3.9e-01
2.3e-01
—
—
—
1.1e+00
5.2e-01
cases:6.40%
controls:4.41%
cases:2.83%
controls:2.26%
—
—
—
—
—
—
cases:4.64%
controls:1.59%
cases:10.46%
controls:6.49%
43
296
629
6419
19
152
653
6563
—
—
—
30
103
617
6358
57
355
488
5118
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
Z03 [45552058]
3.0e-01
1.6e+00
—
—
—
8.7e-01
3.0e-01
cases:1.64%
controls:1.22%
cases:1.19%
controls:0.24%
—
—
—
—
—
—
cases:0.77%
controls:0.33%
cases:1.28%
controls:0.95%
11
82
661
6633
8
16
664
6699
—
—
—
5
21
642
6440
7
52
538
5421
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
4485-9 [3000620]
9.3e-01
8.0e-01
—
—
—
1.6e+00
1.1e+00
cases:1.93%
controls:0.77%
cases:0.89%
controls:0.40%
—
—
—
—
—
—
cases:1.24%
controls:0.25%
cases:1.83%
controls:0.60%
13
52
659
6663
6
27
666
6688
—
—
—
8
16
639
6445
10
33
535
5440
General Practice
1 [38004446]
1 [38004446]
3.9e-01
3.4e-01
9.0e-01
—
7.5e-01
7.1e-01
5.0e-01
cases:17.71%
controls:12.70%
cases:6.25%
controls:4.53%
cases:1.64%
controls:0.67%
—
—
cases:1.34%
controls:0.64%
cases:9.27%
controls:4.78%
cases:21.47%
controls:14.25%
119
853
553
5862
42
304
630
6411
11
45
661
6670
—
9
43
661
6658
60
309
587
6152
117
780
428
4693
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
4.4e-01
3.7e-01
-4.5e-01
—
3.0e-01
6.8e-01
4.7e-01
cases:17.26%
controls:11.79%
cases:9.52%
controls:6.81%
cases:0.74%
controls:1.16%
—
—
cases:1.34%
controls:1.00%
cases:12.06%
controls:6.52%
cases:24.40%
controls:16.85%
116
792
556
5923
64
457
608
6258
5
78
667
6637
—
9
67
661
6634
78
421
569
6040
133
922
412
4551
mometasone
D07AC13 [21602132]
D07AC13 [21602132]
5.7e-01
1.0e+00
—
—
—
7.9e-01
5.5e-01
cases:7.29%
controls:4.26%
cases:3.87%
controls:1.44%
—
—
—
—
—
—
cases:2.63%
controls:1.21%
cases:6.79%
controls:4.02%
49
286
623
6429
26
97
646
6618
—
—
—
17
78
630
6383
37
220
508
5253
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
3.8e-01
5.5e-01
5.9e-01
—
9.5e-01
6.4e-01
3.2e-01
cases:16.22%
controls:11.69%
cases:10.86%
controls:6.55%
cases:1.49%
controls:0.83%
—
—
cases:1.79%
controls:0.70%
cases:13.29%
controls:7.44%
cases:25.50%
controls:19.92%
109
785
563
5930
73
440
599
6275
10
56
662
6659
—
12
47
658
6654
86
481
561
5980
139
1090
406
4383
Emergency Medicine
93 [38004510]
93 [38004510]
2.6e-01
5.4e-01
2.0e-01
—
1.5e-01
5.7e-01
4.7e-01
cases:19.64%
controls:15.83%
cases:13.24%
controls:8.21%
cases:1.34%
controls:1.10%
—
—
cases:1.19%
controls:1.03%
cases:14.22%
controls:8.57%
cases:32.29%
controls:22.91%
132
1063
540
5652
89
551
583
6164
9
74
663
6641
—
8
69
662
6632
92
554
555
5907
176
1254
369
4219
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
-8.0e-03
4.2e-01
—
—
—
1.6e+00
6.7e-01
cases:2.08%
controls:2.10%
cases:0.74%
controls:0.49%
—
—
—
—
—
—
cases:2.63%
controls:0.56%
cases:3.85%
controls:2.01%
14
141
658
6574
5
33
667
6682
—
—
—
17
36
630
6425
21
110
524
5363
econazole
D01AC03 [21601922]
D01AC03 [21601922]
1.6e+00
-1.0e+50
—
—
—
—
—
cases:1.49%
controls:0.31%
cases:0.00%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
10
21
662
6694
0
5
672
6710
—
—
—
—
—
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
72493-0 [43055120]
1.6e+00
—
—
—
—
—
1.2e+00
cases:1.34%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.33%
9
19
663
6696
—
—
—
—
—
6
18
539
5455
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
4.1e-01
4.0e-01
5.1e-01
—
7.9e-01
6.1e-01
5.2e-01
cases:18.75%
controls:13.25%
cases:11.46%
controls:7.95%
cases:2.23%
controls:1.36%
—
—
cases:2.54%
controls:1.16%
cases:13.14%
controls:7.58%
cases:26.24%
controls:17.39%
126
890
546
5825
77
534
595
6181
15
91
657
6624
—
17
78
653
6623
85
490
562
5971
143
952
402
4521
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
4.3e-01
4.3e-01
5.9e-01
—
7.9e-01
6.0e-01
5.1e-01
cases:17.26%
controls:11.91%
cases:10.42%
controls:7.04%
cases:2.23%
controls:1.25%
—
—
cases:2.24%
controls:1.03%
cases:11.59%
controls:6.73%
cases:22.94%
controls:15.15%
116
800
556
5915
70
473
602
6242
15
84
657
6631
—
15
69
655
6632
75
435
572
6026
125
829
420
4644
Erysipelas
A46 [45561706]
A46 [45561706]
2.4e-01
3.6e-01
-1.0e+50
—
—
1.5e+00
2.8e-01
cases:1.93%
controls:1.53%
cases:0.89%
controls:0.63%
cases:0.00%
controls:0.12%
—
—
—
—
cases:1.70%
controls:0.37%
cases:2.57%
controls:1.96%
13
103
659
6612
6
42
666
6673
0
8
672
6707
—
—
11
24
636
6437
14
107
531
5366
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
3.9e-01
4.3e-01
4.5e-01
—
8.1e-01
6.2e-01
5.2e-01
cases:18.15%
controls:13.06%
cases:11.46%
controls:7.77%
cases:2.08%
controls:1.34%
—
—
cases:2.54%
controls:1.15%
cases:13.14%
controls:7.51%
cases:25.87%
controls:17.18%
122
877
550
5838
77
522
595
6193
14
90
658
6625
—
17
77
653
6624
85
485
562
5976
141
940
404
4533
Hepatitis A virus Ab [Presence] in Serum
20575-7 [3016650]
20575-7 [3016650]
1.5e+00
—
—
—
—
—
—
cases:1.49%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
10
22
662
6693
—
—
—
—
—
—
Urinary tract ultrasound examination
KH1AE [2001306329]
KH1AE [2001306329]
1.3e+00
-1.0e+50
—
—
—
—
1.5e+00
cases:1.04%
controls:0.30%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
cases:1.65%
controls:0.37%
7
20
665
6695
0
10
672
6705
—
—
—
—
9
20
536
5453
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
4.2e-01
4.5e-01
6.0e-01
—
8.6e-01
5.8e-01
5.1e-01
cases:16.96%
controls:11.82%
cases:10.42%
controls:6.92%
cases:2.23%
controls:1.24%
—
—
cases:2.39%
controls:1.03%
cases:11.59%
controls:6.81%
cases:22.75%
controls:15.06%
114
794
558
5921
70
465
602
6250
15
83
657
6632
—
16
69
654
6632
75
440
572
6021
124
824
421
4649
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
4.7e-01
5.4e-01
9.0e-01
—
8.6e-01
5.8e-01
4.6e-01
cases:11.16%
controls:7.28%
cases:6.25%
controls:3.72%
cases:1.34%
controls:0.55%
—
—
cases:1.19%
controls:0.51%
cases:7.26%
controls:4.19%
cases:17.98%
controls:12.17%
75
489
597
6226
42
250
630
6465
9
37
663
6678
—
8
34
662
6667
47
271
600
6190
98
666
447
4807
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
4.9e-01
4.1e-01
7.8e-01
—
4.0e-01
5.2e-01
5.0e-01
cases:15.77%
controls:10.34%
cases:8.18%
controls:5.60%
cases:1.93%
controls:0.89%
—
—
cases:1.19%
controls:0.81%
cases:8.66%
controls:5.32%
cases:21.47%
controls:14.22%
106
694
566
6021
55
376
617
6339
13
60
659
6655
—
8
54
662
6647
56
344
591
6117
117
778
428
4695
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
4.7e-01
4.5e-01
8.2e-01
1.0e+50
5.8e-01
5.7e-01
4.6e-01
cases:17.41%
controls:11.66%
cases:9.97%
controls:6.57%
cases:2.23%
controls:1.00%
cases:1.19%
controls:0.00%
cases:1.64%
controls:0.93%
cases:10.82%
controls:6.39%
cases:24.04%
controls:16.65%
117
783
555
5932
67
441
605
6274
15
67
657
6648
8
0
664
6715
11
62
659
6639
70
413
577
6048
131
911
414
4562
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
4.2e-01
4.4e-01
6.0e-01
—
7.9e-01
5.8e-01
5.0e-01
cases:17.11%
controls:11.94%
cases:10.42%
controls:6.98%
cases:2.23%
controls:1.24%
—
—
cases:2.24%
controls:1.03%
cases:11.44%
controls:6.76%
cases:22.75%
controls:15.11%
115
802
557
5913
70
469
602
6246
15
83
657
6632
—
15
69
655
6632
74
437
573
6024
124
827
421
4646
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
4.4e-01
4.3e-01
5.3e-01
—
8.4e-01
6.0e-01
4.5e-01
cases:17.56%
controls:12.02%
cases:10.57%
controls:7.13%
cases:2.08%
controls:1.24%
—
—
cases:2.39%
controls:1.04%
cases:11.90%
controls:6.93%
cases:22.75%
controls:15.75%
118
807
554
5908
71
479
601
6236
14
83
658
6632
—
16
70
654
6631
77
448
570
6013
124
862
421
4611
Cryotherapy
ZXC50 [2001311370]
ZXC50 [2001311370]
1.5e+00
—
—
—
—
—
1.5e+00
cases:1.19%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.42%
8
18
664
6697
—
—
—
—
—
10
23
535
5450
candesartan; oral
C09CA06 [21601829]
C09CA06 [21601829]
2.6e-01
5.8e-01
-3.1e-02
—
9.0e-01
4.3e-01
3.3e-01
cases:6.99%
controls:5.47%
cases:8.04%
controls:4.66%
cases:1.49%
controls:1.53%
—
—
cases:3.58%
controls:1.49%
cases:7.73%
controls:5.17%
cases:11.19%
controls:8.28%
47
367
625
6348
54
313
618
6402
10
103
662
6612
—
24
100
646
6601
50
334
597
6127
61
453
484
5020
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
1.5e+00
—
—
—
—
—
1.0e+00
cases:2.08%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.48%
14
33
658
6682
—
—
—
—
—
7
26
538
5447
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
346 [2001600307]
346 [2001600307]
5.7e-01
—
—
—
—
—
1.4e+00
cases:0.89%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.44%
6
34
666
6681
—
—
—
—
—
10
24
535
5449
Atrial fibrillation/flutter
K78 [2002000605]
K78 [2002000605]
6.5e-01
1.4e+00
1.8e+00
—
—
9.2e-01
2.1e-01
cases:1.64%
controls:0.86%
cases:1.49%
controls:0.36%
cases:0.74%
controls:0.12%
—
—
—
—
cases:0.93%
controls:0.37%
cases:1.28%
controls:1.04%
11
58
661
6657
10
24
662
6691
5
8
667
6707
—
—
6
24
641
6437
7
57
538
5416
Fear sexually transm dis female
X23 [2002001308]
X23 [2002001308]
1.4e+00
—
—
—
—
—
1.2e+00
cases:2.08%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.28%
controls:0.40%
14
34
658
6681
—
—
—
—
—
7
22
538
5451
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
285 [2001600217]
2.0e-01
—
—
—
—
—
1.4e+00
cases:0.74%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:2.02%
controls:0.49%
5
41
667
6674
—
—
—
—
—
11
27
534
5446
Ankle X-ray examination without contrast
NH1AA [2001308235]
NH1AA [2001308235]
5.9e-02
-1.0e+50
—
—
—
—
1.4e+00
cases:1.04%
controls:0.98%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.58%
7
66
665
6649
0
19
672
6696
—
—
—
—
13
32
532
5441
solifenacin; oral
G04BD08 [21602641]
G04BD08 [21602641]
1.4e+00
1.3e+00
—
—
—
—
3.2e-01
cases:3.27%
controls:0.83%
cases:1.49%
controls:0.40%
—
—
—
—
—
—
—
—
cases:1.10%
controls:0.80%
22
56
650
6659
10
27
662
6688
—
—
—
—
6
44
539
5429
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
6.9e-01
6.3e-01
—
—
—
5.6e-01
7.0e-01
cases:8.48%
controls:4.45%
cases:3.27%
controls:1.77%
—
—
—
—
—
—
cases:3.25%
controls:1.89%
cases:7.89%
controls:4.07%
57
299
615
6416
22
119
650
6596
—
—
—
21
122
626
6339
43
223
502
5250
venlafaxine; oral
N06AX16 [21604745]
N06AX16 [21604745]
6.8e-01
6.5e-01
1.3e+00
—
3.3e-01
6.1e-01
7.0e-01
cases:4.91%
controls:2.56%
cases:3.13%
controls:1.65%
cases:1.49%
controls:0.42%
—
—
cases:0.75%
controls:0.54%
cases:2.94%
controls:1.61%
cases:5.50%
controls:2.81%
33
172
639
6543
21
111
651
6604
10
28
662
6687
—
5
36
665
6665
19
104
628
6357
30
154
515
5319
Hysteroscopy
ULC02 [2001306644]
ULC02 [2001306644]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.57%
—
—
—
—
—
—
12
31
533
5442
Clinic/Center
261Q00000X [38004207]
261Q00000X [38004207]
—
—
-1.0e+50
—
—
—
1.4e+00
—
—
—
—
cases:0.00%
controls:0.07%
—
—
—
—
—
—
cases:1.83%
controls:0.48%
—
—
0
5
672
6710
—
—
—
10
26
535
5447
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
4542-7 [3012336]
1.4e+00
—
—
—
—
—
6.3e-01
cases:2.23%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.99%
15
39
657
6676
—
—
—
—
—
10
54
535
5419
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
K58.0 [45596336]
2.7e-01
7.4e-01
—
—
—
—
1.3e+00
cases:1.19%
controls:0.91%
cases:0.74%
controls:0.36%
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.64%
8
61
664
6654
5
24
667
6691
—
—
—
—
13
35
532
5438
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
2.5e-01
7.8e-02
—
—
-1.0e+50
1.3e+00
3.7e-01
cases:2.68%
controls:2.10%
cases:1.19%
controls:1.10%
—
—
—
—
cases:0.00%
controls:0.10%
cases:3.25%
controls:0.88%
cases:4.22%
controls:2.94%
18
141
654
6574
8
74
664
6641
—
—
0
7
670
6694
21
57
626
6404
23
161
522
5312
methenamine; oral
J01XX05 [21603065]
J01XX05 [21603065]
9.8e-01
—
—
—
—
—
1.3e+00
cases:1.34%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:2.02%
controls:0.55%
9
34
663
6681
—
—
—
—
—
11
30
534
5443
Hip X-ray examination
NF1AA [2001307894]
NF1AA [2001307894]
2.8e-01
—
—
—
—
—
1.3e+00
cases:1.34%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.80%
9
68
663
6647
—
—
—
—
—
16
44
529
5429
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
6.4e-01
4.7e-01
—
—
—
5.6e-01
6.6e-01
cases:9.82%
controls:5.44%
cases:4.02%
controls:2.55%
—
—
—
—
—
—
cases:4.79%
controls:2.80%
cases:13.58%
controls:7.51%
66
365
606
6350
27
171
645
6544
—
—
—
31
181
616
6280
74
411
471
5062
Gastroenterology
10 [38004455]
10 [38004455]
5.2e-01
5.1e-01
4.2e-01
—
5.1e-01
6.2e-01
7.7e-01
cases:10.12%
controls:6.25%
cases:4.61%
controls:2.83%
cases:0.74%
controls:0.49%
—
—
cases:0.75%
controls:0.45%
cases:4.64%
controls:2.54%
cases:12.84%
controls:6.38%
68
420
604
6295
31
190
641
6525
5
33
667
6682
—
5
30
665
6671
30
164
617
6297
70
349
475
5124
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
2.8e-01
4.5e-01
6.2e-02
—
6.0e-01
6.9e-01
6.1e-01
cases:6.99%
controls:5.38%
cases:4.17%
controls:2.70%
cases:0.74%
controls:0.70%
—
—
cases:1.19%
controls:0.66%
cases:5.41%
controls:2.80%
cases:11.38%
controls:6.52%
47
361
625
6354
28
181
644
6534
5
47
667
6668
—
8
44
662
6657
35
181
612
6280
62
357
483
5116
Other specified intervertebral disc degeneration
M51.3 [45591865]
M51.3 [45591865]
1.3e+00
—
—
—
—
-1.0e+50
9.1e-01
cases:3.13%
controls:0.88%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:2.02%
controls:0.82%
21
59
651
6656
—
—
—
—
0
25
647
6436
11
45
534
5428
Fibromyalgia
M79.7 [45553272]
M79.7 [45553272]
1.0e+00
1.2e+00
—
—
—
—
1.3e+00
cases:1.79%
controls:0.66%
cases:1.04%
controls:0.31%
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.68%
12
44
660
6671
7
21
665
6694
—
—
—
—
13
37
532
5436
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
TNX10 [2001308560]
9.0e-01
1.1e+00
-1.0e+50
—
-1.0e+50
6.6e-01
1.3e+00
cases:2.38%
controls:0.98%
cases:1.49%
controls:0.49%
cases:0.00%
controls:0.07%
—
—
cases:0.00%
controls:0.09%
cases:0.93%
controls:0.48%
cases:2.57%
controls:0.73%
16
66
656
6649
10
33
662
6682
0
5
672
6710
—
0
6
670
6695
6
31
641
6430
14
40
531
5433
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
65
33
21.69
85.36
2.9
1.5
—
—
—
0
0
171
356
6.09
82.04
2.7
1.5
—
—
—
0
0
50
13
41.46
81.98
1.9
2.2
6.34
2.20
ug/l
—
36
6
384
1607
4.22
75.31
2.8
1.5
—
—
—
0
0
444
2984
2.43
25.89
3.6
2.6
—
—
estimate
—
0
0
264
1547
2.16
19.83
2.8
2.1
—
—
—
0
0
445
3313
2.01
16.00
6.8
5.8
9.08
10.03
umol/l
2.43
424
3151
392
2795
1.96
15.98
6.9
4.2
36.03
36.03
g/l
0.00
380
2631
575
4804
2.33
13.95
10.9
7.6
79.12
77.33
u/l
0.52
554
4552
364
2644
1.82
12.88
16.0
12.6
1.17
1.18
inr
0.08
309
2171
461
3655
1.82
11.62
12.1
9.0
4.01
3.96
e9/l
0.22
411
3199
442
3461
1.80
11.62
5.4
4.1
0.00
0.01
estimate
1.23
96
688
284
1960
1.78
11.56
4.9
3.2
19.02
55.17
e6/l
2.45
230
1478
238
1565
1.80
11.37
5.2
3.5
98.83
95.25
%
1.47
232
1525
419
3244
1.77
11.30
8.9
6.1
1.22
1.22
mmol/l
0.56
361
2785
170
1008
1.92
11.27
3.6
2.8
0.79
0.81
mmol/l
2.32
161
947
293
2061
1.75
11.01
5.1
3.2
6.29
6.66
mmol/l
0.92
247
1745
447
3548
1.77
10.82
6.4
4.4
6.60
6.51
mmol/l
0.35
426
3338
250
1694
1.76
10.63
5.0
3.1
0.25
0.43
e6/l
1.72
195
1220
209
1349
1.80
10.47
3.7
2.6
9.25
8.00
e6/l
0.24
193
1242
36
108
3.46
10.27
5.9
4.4
209.00
118.56
iu/ml
—
9
9
283
2000
1.71
10.26
4.1
2.4
56.69
62.19
u/l
0.64
265
1849
379
2900
1.70
10.20
7.8
5.5
1.22
1.22
mmol/l
0.02
349
2670
160
959
1.88
10.15
2.2
1.9
—
—
—
0
0
428
3401
1.71
9.85
5.2
4.1
0.00
0.00
estimate
0.50
95
694
126
713
1.94
9.46
2.2
2.1
—
—
—
0
0
249
1744
1.68
9.06
2.9
3.1
1301.41
964.15
ng/l
0.31
210
1490
123
700
1.93
9.06
2.8
2.2
5.97
6.14
umol/l
0.05
106
607
427
3441
1.66
8.84
5.3
4.1
19.56
2.27
estimate
0.42
96
716
116
653
1.94
8.81
2.8
2.1
370.11
374.87
nmol/l
0.08
106
613
45
172
2.73
8.54
1.3
1.2
—
—
—
0
0
657
6108
3.84
8.40
26.4
16.8
139.47
139.68
mmol/l
1.29
650
5979
657
6113
3.80
8.29
26.8
16.9
3.93
3.93
mmol/l
0.29
651
5969
114
652
1.90
8.23
2.2
1.9
—
—
—
0
0
270
1975
1.61
8.05
5.6
4.0
10.78
6.54
mg/mmol
0.63
167
1130
209
1439
1.66
7.92
1.6
1.5
2.08
2.22
g/l
0.64
122
863
125
747
1.83
7.85
10.2
4.1
1.07
1.04
mmol/l
0.61
115
677
76
385
2.10
7.72
1.8
1.7
—
—
—
0
0
161
1043
1.71
7.65
4.3
2.8
2.11
1.17
e6/l
0.69
96
518
88
473
1.99
7.61
1.8
1.9
—
—
—
0
0
106
615
1.86
7.29
6.7
6.4
-0.19
1.10
mmol/l
2.22
85
513
214
1512
1.61
7.20
1.9
1.7
0.92
1.04
mg/l
0.45
173
1172
82
447
1.95
6.80
1.7
1.5
—
—
—
0
0
94
540
1.86
6.66
4.9
2.8
1.49
2.17
mmol/l
0.99
81
471
64
324
2.08
6.52
5.1
1.8
16.74
6.86
iu/ml
0.81
18
75
251
1874
1.54
6.51
5.1
4.2
0.00
0.00
estimate
0.80
91
675
643
6003
2.50
6.35
24.8
14.6
21.46
21.21
mg/l
0.07
558
4909
630
5837
2.19
6.26
21.8
14.2
80.90
81.34
ml/min/173m2
0.20
608
5387
141
938
1.64
5.93
4.5
3.0
3.25
4.45
e6/l
0.95
74
408
26
91
2.93
5.84
2.1
1.4
—
—
—
0
0
535
4752
1.61
5.80
6.5
4.5
13.41
12.27
mm/h
1.12
507
4451
320
2558
1.48
5.79
4.9
4.0
0.04
0.04
estimate
0.06
80
569
113
716
1.69
5.71
2.0
1.8
—
—
—
0
0
24
83
2.96
5.51
1.2
1.4
—
—
—
0
0
48
233
2.14
5.47
1.7
2.2
1.74
1.51
g/l
0.79
41
209
16
43
3.79
5.39
1.3
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
34
143
2.45
5.39
3.3
2.7
0.45
0.39
iu/ml
0.30
18
85
36
156
2.38
5.35
3.1
2.8
1.40
2.13
index
0.46
20
72
251
1938
1.47
5.29
2.5
2.1
112.46
179.11
u/l
1.26
236
1843
382
3205
1.44
5.12
2.9
2.5
80.60
79.17
nmol/l
0.43
344
2915
349
2880
1.44
5.12
2.5
2.1
99.26
99.00
pmol/l
0.03
183
1436
106
682
1.66
5.04
2.1
1.8
—
—
—
0
0
149
1041
1.55
5.04
1.7
1.7
1172.01
1226.02
nmol/l
0.30
118
781
52
272
1.99
4.88
2.2
2.0
1518.20
4743.58
u/l
1.08
21
117
177
1295
1.50
4.81
1.7
1.6
—
—
—
0
0
573
5242
1.62
4.76
5.7
5.1
14.74
14.71
pmol/l
0.12
542
4873
32
140
2.35
4.68
1.3
1.7
—
—
—
0
0
7
5
14.12
4.58
4.0
3.4
—
—
—
0
0
126
866
1.56
4.56
4.3
2.3
21.02
21.52
%
0.19
111
809
15
36
4.24
4.54
1.7
2.1
—
—
—
0
0
108
717
1.60
4.53
7.7
5.8
—
—
—
0
0
40
197
2.10
4.43
2.5
1.8
—
—
—
0
0
16
50
3.25
4.36
1.2
1.5
—
—
—
0
0
53
292
1.88
4.30
5.5
3.3
1.11
1.95
mmol/l
0.83
44
225
218
1694
1.42
4.26
3.0
2.3
2.92
2.89
mg/l
0.07
184
1453
466
4121
1.42
4.25
4.2
3.1
49.89
41.61
u/l
1.06
445
3877
134
948
1.52
4.24
4.0
2.3
2.25
2.40
g/l
2.63
119
881
42
215
2.02
4.21
2.5
1.8
—
—
—
0
0
446
3918
1.41
4.20
3.3
3.2
—
—
—
0
0
196
1498
1.43
4.18
2.9
2.4
313.99
312.48
umol/l
0.07
175
1324
237
1879
1.40
4.10
1.8
1.7
21.61
21.21
nmol/l
0.14
209
1594
70
426
1.72
4.10
2.0
2.3
2.47
5.39
ug/l
3.65
58
377
32
149
2.20
4.09
2.3
1.6
—
—
—
0
0
624
5884
1.80
4.03
7.3
6.2
1.83
1.85
mu/l
0.15
597
5520
24
99
2.48
4.01
1.7
1.3
218.00
171.05
au/ml
—
5
30
657
6309
2.55
4.01
17.1
11.8
24.04
23.30
u/l
0.63
647
6133
140
1013
1.48
3.96
4.1
2.3
12.07
12.85
umol/l
0.67
127
941
30
139
2.21
3.89
1.3
1.5
—
—
—
0
0
10
19
5.33
3.84
2.8
2.3
0.60
0.62
mmol/l
—
10
19
93
624
1.57
3.72
3.6
2.3
29.52
37.05
u/l
1.41
73
513
127
913
1.48
3.70
2.0
2.2
196.60
107.52
ug/g
0.70
92
712
605
5681
1.63
3.67
7.8
6.1
38.96
38.72
mmol/mol
0.29
575
5323
153
1142
1.44
3.67
4.2
3.9
139.34
288.05
ng/l
0.71
109
836
288
2393
1.35
3.63
4.5
3.3
2.36
2.37
mmol/l
0.27
257
2190
83
546
1.59
3.62
5.5
3.1
105.96
78.16
ng/l
1.51
74
482
24
105
2.33
3.56
1.3
1.4
—
—
—
0
0
41
222
1.90
3.54
1.2
1.4
363.83
302.15
ug/g
0.83
24
128
25
112
2.28
3.52
1.4
1.4
—
—
—
0
0
18
69
2.65
3.49
1.3
1.1
—
—
—
0
0
18
69
2.65
3.49
1.4
1.6
—
—
—
0
0
374
3247
1.34
3.46
3.9
3.1
104.58
84.51
ug/l
1.60
346
3039
81
536
1.58
3.45
2.6
3.1
184.53
81.50
u/ml
0.28
81
517
92
635
1.52
3.25
1.8
1.5
1.37
1.37
%
0.02
78
561
55
338
1.68
3.15
1.7
1.7
—
—
—
0
0
26
125
2.12
3.12
1.4
1.4
—
—
—
0
0
76
509
1.56
3.08
2.3
2.5
62.73
68.10
ml/min/173m2
0.36
26
223
211
1706
1.34
3.08
1.3
1.3
0.62
1.69
u/ml
2.23
52
466
21
94
2.27
2.99
1.4
1.6
—
—
—
0
0
11
32
3.48
2.91
2.3
1.3
—
—
—
0
0
12
38
3.20
2.86
1.1
1.3
—
—
—
0
0
22
103
2.17
2.83
1.3
1.3
—
—
—
0
0
189
1520
1.34
2.83
4.9
4.2
1.02
2.00
kg/l
0.50
132
1021
38
217
1.80
2.82
6.0
1.7
0.22
0.23
g/l
0.24
38
208
254
2132
1.31
2.81
3.9
2.8
29.41
28.80
u/l
0.19
244
2017
31
166
1.91
2.81
4.3
3.7
1.32
2.28
ratio
1.36
22
101
598
5661
1.49
2.81
4.7
4.2
1.31
1.24
mmol/l
2.10
553
5220
14
54
2.63
2.72
2.1
3.2
57.36
53.58
%
0.31
14
48
35
198
1.81
2.69
1.1
1.1
—
—
—
0
0
665
6488
2.69
2.65
36.6
22.9
267.65
263.29
e9/l
1.02
660
6372
11
35
3.18
2.65
1.1
1.4
—
—
—
0
0
665
6490
2.66
2.61
36.6
22.9
4.33
4.40
e12/l
3.05
659
6353
665
6490
2.66
2.61
37.2
23.1
39.22
39.59
%
1.26
660
6427
62
414
1.55
2.57
2.6
3.1
181.96
195.63
ng/l
0.08
56
389
222
1848
1.30
2.57
4.4
3.5
0.00
0.01
estimate
1.34
75
567
264
2249
1.29
2.55
4.3
3.7
24.90
58.30
ng/l
0.64
175
1490
27
143
1.93
2.54
1.6
1.5
—
—
—
0
0
17
75
2.30
2.52
1.6
1.3
—
—
—
0
0
38
225
1.73
2.52
6.1
1.7
1.17
1.22
g/l
0.29
38
213
17
76
2.27
2.46
1.6
1.3
—
—
—
0
0
17
76
2.27
2.46
1.6
1.3
—
—
—
0
0
13
51
2.58
2.45
1.4
1.0
—
—
—
0
0
70
486
1.49
2.44
2.4
2.5
17.66
20.80
au/ml
—
9
45
33
190
1.77
2.42
1.1
1.3
—
—
—
0
0
34
198
1.76
2.40
1.1
1.1
—
—
—
0
0
9
27
3.36
2.40
3.2
2.2
0.78
0.81
index
—
9
27
5
8
6.29
2.37
1.2
1.1
—
—
—
0
0
11
40
2.78
2.28
1.1
1.3
—
—
—
0
0
53
357
1.53
2.15
2.9
2.5
123.11
129.19
g/l
1.51
53
347
11
42
2.65
2.15
1.3
1.6
11.53
11.23
umol/l
0.06
11
36
168
1378
1.29
2.13
3.3
2.6
2.47
2.45
mmol/l
0.54
145
1250
82
604
1.41
2.12
3.9
3.3
—
—
—
0
0
17
82
2.10
2.08
1.6
1.2
—
—
—
0
0
17
82
2.10
2.08
1.6
1.2
—
—
—
0
0
17
82
2.10
2.08
1.6
1.2
—
—
—
0
0
35
215
1.66
2.07
1.7
1.5
0.00
0.11
iu/ml
—
5
25
6
15
4.03
2.04
1.0
1.2
—
—
—
0
0
19
97
1.99
2.02
1.0
1.1
2.38
1.61
eliau/ml
—
10
48
38
241
1.61
2.00
1.5
1.2
6.85
8.03
u/ml
—
10
37
38
241
1.61
2.00
1.5
1.2
19.00
2.19
u/ml
—
8
22
66
473
1.44
1.99
4.4
3.6
4.87
4.56
pmol/l
0.47
57
415
26
149
1.77
1.97
2.3
2.4
—
—
—
0
0
160
1323
1.27
1.90
1.7
1.7
447.16
29837696.79
pmol/l
1.56
129
1106
40
262
1.56
1.86
1.6
1.6
8.28
10.40
u/ml
—
9
50
5
12
4.19
1.82
1.2
1.1
—
—
—
0
0
5
12
4.19
1.82
1.6
1.2
—
—
—
0
0
15
73
2.08
1.81
1.4
1.5
—
—
—
0
0
9
35
2.59
1.80
2.0
1.3
61.89
69.03
umol/l
—
9
35
98
764
1.33
1.80
5.4
4.8
33.80
33.58
%
0.07
66
498
8
29
2.78
1.79
1.6
2.8
—
—
—
0
0
68
503
1.39
1.74
1.4
1.3
338.23
183.13
u/ml
0.35
63
468
42
283
1.52
1.74
1.6
2.2
37.06
40.67
u/l
0.47
34
256
5
13
3.87
1.72
1.4
2.2
2.60
1.84
ratio
—
5
13
34
219
1.58
1.71
1.1
1.4
0.37
0.31
mg/l
0.25
15
77
11
48
2.31
1.71
1.5
1.4
—
—
—
0
0
69
514
1.38
1.70
2.9
2.8
65.82
67.45
g/l
0.76
57
479
66
489
1.39
1.68
1.6
1.5
—
—
—
0
0
65
481
1.39
1.67
2.8
2.3
0.42
0.66
e6/l
0.40
65
451
36
237
1.55
1.66
3.8
2.1
2.87
2.99
g/l
0.28
30
220
6
20
3.02
1.58
1.0
1.2
—
—
—
0
0
34
225
1.54
1.54
2.6
2.1
9.68
10.11
g/l
0.18
27
207
37
250
1.51
1.53
3.4
2.8
25.43
25.49
mmol/l
0.04
37
244
43
300
1.46
1.53
1.3
1.5
—
—
—
0
0
19
108
1.78
1.52
1.4
1.3
—
—
—
0
0
37
251
1.50
1.51
3.8
2.1
3.46
3.76
g/l
0.80
31
235
28
178
1.60
1.51
2.1
1.8
188.21
185.72
ug/l
0.01
28
159
37
252
1.50
1.48
3.8
2.1
7.96
7.59
g/l
0.60
31
235
37
252
1.50
1.48
3.8
2.1
4.25
4.32
g/l
0.17
31
235
606
5861
1.33
1.47
6.4
5.1
5.88
5.82
mmol/l
0.71
563
5410
625
6073
1.39
1.47
6.7
5.7
2.70
2.79
mmol/l
1.67
584
5666
23
140
1.67
1.46
2.8
1.9
118.00
128.32
g/l
1.08
13
109
50
363
1.41
1.45
1.6
1.3
—
—
—
0
0
7
28
2.52
1.45
1.7
1.2
14.86
8.39
mm/h
—
7
28
11
52
2.13
1.45
1.2
1.3
—
—
—
0
0
6
138
0.43
1.41
2.0
1.8
—
—
—
0
0
10
46
2.19
1.40
1.1
1.0
—
—
—
0
0
28
182
1.56
1.39
1.4
1.3
728.43
483.11
mg/l
0.42
28
171
5
17
2.95
1.36
1.0
1.0
—
—
—
0
0
298
2705
1.18
1.36
2.2
1.9
1.35
1.32
mmol/l
0.30
250
2305
40
285
1.43
1.31
4.7
3.2
53.09
46.74
%
0.89
40
280
14
76
1.86
1.30
1.0
1.1
—
—
—
0
0
5
18
2.79
1.28
1.0
1.1
521.00
372.00
pmol/l
—
5
13
9
45
2.01
1.23
1.3
1.4
—
—
—
0
0
9
45
2.01
1.23
1.3
1.4
—
—
—
0
0
9
45
2.01
1.23
1.3
1.4
—
—
—
0
0
5
19
2.64
1.22
1.2
1.1
—
—
—
0
0
5
19
2.64
1.22
1.2
1.1
—
—
—
0
0
616
5997
1.31
1.19
5.9
5.0
4.70
4.81
mmol/l
2.14
579
5615
8
38
2.12
1.18
1.1
1.2
—
—
—
0
0
8
39
2.06
1.15
1.6
1.4
14.88
27.91
ug/l
—
8
39
18
111
1.64
1.13
1.6
1.3
—
—
—
0
0
18
111
1.64
1.13
1.3
1.2
2.10
5.19
u/ml
—
10
42
18
111
1.64
1.13
1.6
1.3
—
—
—
0
0
7
30
2.35
1.12
1.7
1.9
1.34
1.00
nmol/l
—
7
22
13
73
1.80
1.11
1.0
1.1
—
—
—
0
0
31
219
1.44
1.09
3.3
2.3
1.23
0.67
g/l
0.30
24
195
13
74
1.77
1.07
2.5
1.7
5.05
57.34
u/ml
0.52
13
74
612
5966
1.28
1.06
5.7
4.9
1.54
1.59
mmol/l
2.15
572
5555
10
52
1.94
1.06
2.9
2.2
—
—
—
0
0
19
122
1.57
1.03
1.9
1.5
—
—
—
0
0
7
34
2.07
1.03
1.3
1.1
17.18
28.80
nmol/l
—
7
26
42
317
1.35
1.02
1.6
1.5
—
—
—
0
0
9
48
1.89
1.00
1.1
1.6
—
—
—
0
0
33
241
1.39
0.98
1.5
1.3
272.77
247.50
miu/ml
0.15
13
113
5
23
2.18
0.98
1.6
1.3
—
—
—
0
0
23
157
1.48
0.97
1.3
1.4
32.59
15.16
e6/l
0.22
17
114
28
199
1.42
0.97
1.6
1.2
—
—
—
0
0
9
51
1.77
0.95
1.0
1.0
—
—
—
0
0
23
158
1.47
0.94
1.3
1.5
9.67
129.50
e6/l
2.16
18
119
10
55
1.83
0.92
1.2
1.9
—
—
—
0
0
6
29
2.08
0.89
1.2
1.2
—
—
—
0
0
6
29
2.08
0.89
1.2
1.2
—
—
—
0
0
14
87
1.62
0.88
4.4
6.4
296.64
377.27
umol/l
1.87
14
81
76
637
1.22
0.84
3.1
3.9
3.32
8.67
ug/l
3.31
60
508
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
26
188
1.40
0.84
1.3
1.2
—
—
—
0
0
6
115
0.52
0.83
1.3
1.5
40.52
51.63
ug/l
—
6
115
70
583
1.22
0.83
1.1
1.2
139.24
154.22
u/ml
0.13
23
239
14
89
1.59
0.81
1.2
1.2
0.20
0.18
nmol/l
—
9
66
6
34
1.77
0.76
1.5
1.1
—
—
—
0
0
6
34
1.77
0.76
4.7
3.8
818.17
1001.88
u/ml
—
6
34
11
67
1.65
0.75
1.0
1.1
—
—
—
0
0
17
116
1.48
0.75
3.8
2.3
16.15
15.99
%
0.08
17
116
160
1446
1.14
0.73
1.3
1.4
21.73
29.99
iu/ml
1.01
46
459
14
92
1.53
0.72
1.7
1.7
—
—
—
0
0
9
56
1.62
0.72
1.1
1.1
—
—
—
0
0
7
40
1.76
0.71
1.0
1.1
—
—
—
0
0
22
160
1.39
0.71
2.7
1.4
—
—
—
0
0
15
216
0.69
0.70
1.3
1.1
1.76
1.63
g/l
0.65
15
216
16
110
1.47
0.69
1.3
1.1
1.29
1.74
u/ml
—
7
35
7
43
1.63
0.67
1.1
1.1
1.09
1.06
ratio
—
7
37
27
349
0.76
0.66
1.4
1.6
965.60
991.37
mu/l
0.05
19
289
5
29
1.73
0.64
1.0
1.2
—
—
—
0
0
33
261
1.28
0.63
1.5
1.7
—
—
—
0
0
59
500
1.20
0.62
1.4
1.7
3.65
3.46
mmol/l
0.47
32
356
0
20
0.00
0.60
0.0
2.1
—
41.77
—
0
20
61
521
1.19
0.59
5.4
3.6
1.23
1.23
mmol/l
0.44
51
451
16
116
1.39
0.55
2.4
3.4
158.74
2781.46
u/ml
0.66
16
111
45
378
1.20
0.53
1.1
1.1
—
—
—
0
0
16
118
1.36
0.50
1.3
1.5
—
—
—
0
0
11
156
0.70
0.50
1.3
1.6
—
—
—
0
0
7
48
1.46
0.47
1.1
1.2
—
—
—
0
0
7
48
1.46
0.47
1.1
1.2
—
—
—
0
0
13
94
1.39
0.46
1.1
1.1
—
—
—
0
0
146
1352
1.10
0.46
1.4
1.3
8.83
10.78
u/ml
0.15
53
518
14
103
1.37
0.45
1.1
1.1
—
—
—
0
0
11
78
1.42
0.43
1.2
1.1
102.00
98.73
%
0.14
11
71
5
31
1.62
0.43
2.8
2.0
40.42
46.06
ug/l
—
5
31
0
15
0.00
0.41
0.0
1.1
—
102.20
—
0
15
29
241
1.21
0.40
1.4
1.4
234.76
286.46
pmol/l
0.12
29
236
5
34
1.47
0.40
1.0
1.2
73.60
74.25
u/l
—
5
28
8
60
1.34
0.40
2.8
3.7
—
—
—
0
0
73
656
1.13
0.40
1.8
1.9
3.35
3.25
ratio
0.30
50
513
5
35
1.43
0.39
1.6
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.8
—
5.88
—
0
12
5
36
1.39
0.38
4.4
2.4
505.00
612.50
ml
—
5
24
5
36
1.39
0.38
1.6
1.0
—
—
—
0
0
9
69
1.31
0.37
1.1
1.2
—
—
—
0
0
6
46
1.31
0.33
1.0
1.2
—
—
—
0
0
49
444
1.11
0.26
1.2
1.3
33.44
28.73
iu/l
0.35
40
395
11
135
0.81
0.22
1.0
1.1
0.36
2.29
u/ml
—
6
69
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
25
226
1.11
0.15
2.7
1.9
2.69
29.62
iu/l
0.54
12
92
21
233
0.90
0.14
1.4
1.5
—
—
—
0
0
19
211
0.90
0.13
1.5
1.6
57.44
58.70
ug/l
0.04
14
179
18
198
0.91
0.11
1.3
1.5
1.18
1.11
ratio
—
10
131
18
198
0.91
0.11
1.3
1.5
1.13
1.19
ratio
—
10
131
18
198
0.91
0.11
1.3
1.5
1.08
0.97
ratio
—
10
131
5
44
1.14
0.10
1.4
1.5
—
448.33
—
0
6
5
45
1.11
0.10
1.4
1.6
—
22.43
—
0
7
5
46
1.09
0.09
1.2
1.4
—
—
—
0
0
18
196
0.92
0.09
1.3
1.5
—
—
—
0
0
8
74
1.08
0.07
1.1
1.1
—
—
—
0
0
8
77
1.04
0.07
4.5
2.2
13.18
13.36
%
—
8
77
7
80
0.87
0.07
1.3
1.1
—
—
—
0
0
21
199
1.06
0.04
1.2
1.2
—
—
—
0
0
12
128
0.94
0.02
3.4
3.7
26.29
23.97
mg/l
—
7
80
23
225
1.02
0.00
3.4
2.9
25.50
783.01
u/ml
0.69
16
197
26
259
1.00
0.00
1.3
1.9
3.09
2.45
mg/l
0.24
21
197
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
3.3
—
0.67
—
0
9
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.2
—
9.70
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
72
0.97
-0.00
1.6
2.2
1.18
1.20
mmol/l
—
7
72
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
36.44
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
21.68
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
8.86
—
0
5
6
64
0.94
-0.00
1.3
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
6.7
—
5.58
—
0
6
7
70
1.00
-0.00
1.3
1.1
—
—
—
0
0
6
66
0.91
-0.00
1.3
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
85.00
—
0
6
7
72
0.97
-0.00
1.6
2.2
105.57
105.51
mmol/l
—
7
72
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
6
68
0.88
-0.00
1.3
1.1
—
—
—
0
0
6
68
0.88
-0.00
1.3
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint N14_VULVAL_HSIL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_VULVAL_HSIL | 1.464 [1.23, 1.74] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.114 |
During the follow-up period (1.1.1998 — 31.12.2019), 378 out of 2373 females with N14_VULVAL_HSIL died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have N14_VULVAL_HSIL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.119% | No data |
| 5 | 0.772% | No data |
| 10 | 2.04% | No data |
| 15 | 3.618% | No data |
| 20 | 6.301% | No data |
Relationships between endpoints
↥Index endpoint: N14_VULVAL_HSIL – HSIL lesion of the vulva
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data